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Cell surface receptor proteins are important gatekeepers. They enable cells
to react to their surroundings by receiving and propagating chemical signals
through the cell membrane. Countless such reactions occur in the cells of
our bodies every moment to keep us alive. Hence, understanding how these
molecules operate helps us to improve our health and the quality of our
life.
In this Thesis, we discuss the activation of two cell signaling-related pro-
teins, CD44 and JAK2. CD44 is a cell surface receptor for a carbohydrate
called hyaluronan. Through hyaluronan binding, CD44 is involved in vari-
ous signaling cascades that regulate, e.g., cell–cell interactions as well as cell
differentiation, proliferation, and survival. JAK2 is a non-receptor tyrosine
kinase — an intracellular signaling protein that binds to cytokine recept-
ors, forming a receptor–JAK signaling complex. Through this interaction,
JAK2 mediates central physiological functions, including haematopoiesis
and immune response.
Despite their physiological significance, the understanding of these pro-
teins is incomplete because their atomic-level operating principles have not
yet been fully elucidated. Therefore, we use biomolecular simulations to
shed light into the function and regulation of these proteins and their cog-
nate molecules. In the case of CD44, we expand the current knowledge on
the details of its hyaluronan binding. We also show how N -glycosylation
of the receptor can modulate the ligand binding by altering its binding site
preference. In the case of JAK2, we find how the activation of the signaling
complex is controlled by intracellular dimerization and proper orientation
through specific membrane binding.
Our work provides novel atomic-level insight into the functions and
interactions of the studied proteins. The results can be useful in drug
development — especially in the search for new drug binding sites, for
example, at glycosylation, dimerization, or membrane binding interfaces of
proteins. Finally, this work highlights the added value gained by bridging




Solupinnan reseptoriproteiinit ovat tärkeitä portinvartijoita. Ne vastaanot-
tavat solunulkoisia signaaleja ja välittävät niitä eteenpäin käynnistämällä
solujen sisäisiä kemiallisia kaskadeja. Lukemattomia tällaisia reaktioita ta-
pahtuu kehomme soluissa joka hetki, jotta pysyisimme hengissä. Siksi näiden
molekyylien ja niiden toiminnan ymmärtäminen on keskeistä esimerkiksi
sairauksien hoidossa.
Tässä väitökirjassa käsittelemme kahden solun signalointiin liittyvän
proteiinin, CD44:n ja JAK2:n, aktivaatiota. CD44 on luonnollisen hiilihy-
draattipolymeerin, hyaluronihapon, solupintareseptori. Hyaluronihapon si-
toutumisen kautta CD44 osallistuu erilaisiin signalointikaskadeihin, jotka
säätelevät esimerkiksi solujen välistä vuorovaikutusta sekä solujen kasvua,
lisääntymistä ja eloonjäämistä. JAK2 puolestaan on tyrosiinikinaasi, joka
ei kuitenkaan itse toimi reseptorina. Se on signalointiproteiini, joka sitou-
tuu sytokiinireseptoreihin muodostaen signalointikompleksin, johon kuuluu
sekä JAK2 että reseptori. Tämän vuorovaikutuksen kautta JAK2 säätelee
monia kehomme prosesseja, kuten hematopoieesia ja immuunivastetta.
Käsitys näiden proteiinien toimintaperiaatteista on edelleen puutteellis-
ta, sillä niiden molekyylitason toimintaa ei vielä täysin ymmärretä. Tämän
vuoksi käytämme tietokonesimulaatioita valaisemaan kyseisten proteiinien
toimintaa ja säätelyä nanomittakaavassa. CD44:n tapauksessa laajennam-
me nykyistä käsitystä sen ja hyaluronihapon vuorovaikutuksesta. Näytämme
myös, kuinka CD44:n glykosylaatio voi moduloida hyaluronihapon sitoutu-
mista muuttamalla sen sitoutumispaikkaa. JAK2:n tapauksessa osoitamme,
kuinka sekä dimerisaatio että sitoutuminen solukalvoon ohjaavat signaloin-
tikompleksin aktivaatiota.
Työmme avulla saavutettiin uutta tietoa tutkittujen proteiinien toimin-
nasta ja vuorovaikutuksista. Tuloksista voi olla hyötyä lääkekehityksessä
— erityisesti etsittäessä uusia lääkeaineiden sitoutumiskohtia esimerkiksi
proteiinien glykosylaatio-, dimerisaatio- tai kalvoonsitoutumisrajapinnois-
ta. Työ korostaa myös tietokonesimulaatioiden ja kokeellisten tekniikoiden
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Vattulainen, Pavĺına Řezáčová, and Hector Martinez-Seara.
”N-Glycosylation can selectively block or foster different receptor–
ligand binding modes”. Scientific Reports, 11(5239). 2021.
III Stephan Wilmes, Maximillian Hafer, Joni Vuorio, Julie A.
Tucker, Hauke Winkelmann, Sara Löchte, Tess A. Stanly,
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Note: amino acids at specific positions in a protein are referred to with
the single-letter code followed by their position in the canonical primary
sequence of the polypeptide chain. For example, valine (V) at position
617 is written as V617. Amino acid substitutions at the protein level are
indicated by adding the single-letter abbreviation of the substituting amino
acid at the end of the code. For example, V617F denotes that amino acid
617 (valine, V) is mutated to phenylalanine (F).
Chapter 1
Introduction
Life consists of tiny functional units called cells [1]. They are microscopic
systems evolved to adapt, propagate, and protect their hereditary informa-
tion [2]. Different cells achieve these tasks with different means, with some
operating as a single unit while others form complex multicellular organ-
isms. Yet, every cell type shares a mutual chemical blueprint, governed by
a few simple principles [3]. Firstly, they are enclosed in a membrane made
of fat-like substances called lipids. Secondly, their hereditary information
is encoded in a polymer of deoxyribonucleic acid (DNA). Finally, the in-
formation encoded in DNA is transcribed into proteins, which comprise the
vast functional machinery that keeps the cells operating.
After construction and post-processing, proteins are localized in vari-
ous intra and extracellular loci to perform their respective functions. For
example, some of them are secreted from the cell to work as chemical mes-
sengers, such as cytokines, or structural units of connective tissues, such as
collagen. Others remain inside the cell as structural units, such as actin.
Furthermore, a significant fraction of all proteins end up in lipid mem-
branes, where they perform critical signaling and transport functions [3].
The cell surface receptor proteins in the outer cell membrane or plasma
membrane (PM) are especially important, as they receive cues from the
immediate surroundings and subsequently convert them to intracellular sig-
nals that guide the actions of the cell. Due to their central role and location,
they are also the prime targets of the pharmaceutical industry [4].
The operational principles of proteins are typically complex and involve
interactions with several other molecules. For example, a large portion of
eukaryotic proteins are decorated with carbohydrate moieties or glycans
that share a vital — yet often unknown — role in the function of their
parent protein [5,6]. Furthermore, in many cases, a particular protein needs
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to be activated only under specific conditions, which are controlled by the
binding of a messenger molecule called a ligand. If a disorder, such as a
genetic mutation, forces the protein to be constitutively active or inactive
even without its ligand, the resulting physiological imbalance can lead to
the formation of a disease, such as cancer [3]. To treat such conditions,
researchers try to understand how different proteins work, especially how
they interact with other molecules and what causes them to malfunction
in a pathological state. This field of uncovering the physical underpinnings
of biomolecules’ function is called molecular biophysics [2].
The backbone of biophysical research lies in various experimental meth-
ods. However, the small size of the studied biomolecules often poses a major
challenge for these methods, as they are limited by the spatial and tem-
poral resolutions required to probe such nano-sized objects. For instance,
obtaining an Ångström-resolution view of a water-soluble protein typically
requires crystallization of the target molecule, thus eliminating its dynam-
ics. In many cases, the molecules under study are also so fragile that the
measurement itself imposes a perturbation to their natural structure [7].
Moreover, it is challenging to visualize proteins in an in vivo environment
to detect their full range of interactions with other biomolecules.
Fortunately, theoretical and computational methods can complement
experiments by overcoming some of their typical limitations. Indeed, mod-
eling and simulation techniques, such as molecular dynamics (MD) simu-
lations, provide a particularly appealing route to study the interactions of
proteins and other biomolecules with atomistic resolution. This has been
made possible by improvements in both time and length scales reachable by
simulations through novel multiscale approaches and ever-increasing com-
puter capacity [8]. The accuracy of computational models is also constantly
evolving. Especially when combined with appropriate experiments, simula-
tions can help to decipher the molecular underpinnings of various diseases
or to uncover the operational principles of physiologically important bio-
molecules and thus improve our health.
1.1 Objectives and Scope of the Thesis
This Thesis covers MD simulation studies of two PM-associated proteins
and is thereby divided into two parts. The first part focuses on a receptor
protein called CD44 [9–11] and its interaction with its carbohydrate lig-
and, hyaluronic acid (HA) also known as hyaluronan [11, 12]. The CD44–
hyaluronan interaction is key in mediating cellular motility and adhesion
in both health and disease, such as the metastasis of cancer [13]. The
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interaction is also heavily modulated by N -linked glycosylations on the
hyaluronan-binding domain (HABD) of CD44 [14–17].
The second part focuses on a protein family called Janus kinases (JAKs).
They bind specific cytokine receptors at the PM and transmit essential
chemical signals related to cell differentiation, proliferation, and survival via
phosphate-transferring reactions [18, 19]. Their name stems from the two-
faced Roman god, Janus, as they possess two nearly-identical phosphate-
transferring domains. Importantly, specific mutations in JAK2 have been
implicated in the onset of blood cancers, such as leukaemia [20].
The simulation results presented in this Thesis are predominantly linked
to experiments conducted in collaboration with our partner groups. Yet,
the focus of this work lies on communicating the in silico parts of each
research project.
The first objective of this Thesis is to provide an atomic-scale under-
standing of the dynamics associated with the binding of HA to its CD44
receptor. Currently, there is one crystallographic 3D structure describ-
ing the CD44 HABD–HA interaction [11]. However, multiple studies have
listed several HA binding amino acid residues that seemingly contradict
with this crystallographic view [21–23]. While some of these studies have
proposed a large-scale conformation shift to account for the observed dis-
crepancies [10,23–25], others have coined the existence of secondary binding
modes [10]. To gain a better understanding of the CD44–HA binding, we
used MD simulations to couple HABD with its HA ligand in a spontaneous
manner. The central question was whether there are secondary HA binding
modes, and if so, what is their biological role.
The second objective is to decipher the role of glycosylations in mediat-
ing the CD44–HA interaction. Current findings show a correlation between
the N -glycosylation of CD44 and the measured HA binding levels [14]. A
negatively charged group of glycans called sialic acids — often associated
with cancerous phenotypes — are known to act as prime regulators of HA
binding [17,26,27]. Some studies also indicate certain glycosylation sites on
CD44 HABD to be more important in controlling ligand binding than oth-
ers [16]. Because of such findings, previous simulation efforts to study the
glycosylations of CD44 have modeled CD44 HABD only in a partially glyc-
osylated state without the HA ligand [27]. To obtain a more comprehensive
picture, we modeled a fully N -glycosylated CD44 HABD, expressing sev-
eral realistic glycan profiles, together with the HA ligand. Continuing the
work from our first study, the key question was: can the glycosylations
control receptor affinity by acting as switches between different HA bind-
ing modes. We also aimed to uncover the role of the different glycan profiles
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in the recognition of HA.
The third objective is related to the second part of the Thesis: un-
derstanding the dimerization of JAKs. JAKs are a four-member fam-
ily of signaling proteins constantly bound to a cytokine receptor with a
1:1 stoichiometry. In a normal state, the ligand-induced dimerization of
such receptor–JAK complexes controls their activation as signaling mo-
lecules [18,19]. In a pathological state, however, oncogenic gain-of-function
mutations keep the complexes constitutively active through an unknown
mechanism — even in the absence of the ligand [28]. One plausible explan-
ation is that these mutations, particularly the V617F mutation in JAK2,
enhance the dimerization affinity of the cytosolic phosphate-transferring
domains [29, 30]. Our central idea was to test this hypothesis using MD
simulations. Additional goals involved deciphering the dynamics and relat-
ive organization of the four-domain structure of JAK2 as well as evaluating
its interactions with a model lipid bilayer.
This Thesis places the work done into a broader context and evaluates
it critically based on the works of others. The analysis culminates into a
state-of-the-art view of the fields of CD44 and JAK research.
1.2 Structure of the Thesis
This Thesis is organized as follows. After the Introduction, Chapter 2
presents an overview of central biological concepts discussed in this Thesis.
Here, the main focus lies on the two primary target proteins of this Thesis
— CD44 and JAK2. The following Chapter 3 presents the theoretical back-
ground behind the methods used in this Thesis, focusing in particular on
the MD simulation method. The Chapter closes by describing the simula-
tion systems and models used in the included publications.
Chapters 4–6 present the findings of this Thesis. Chapter 4, based
on Publication I, classifies three binding modes for the non-glycosylated
CD44–HA interaction. Chapter 5 extends this work by exploring how glyc-
osylations modify the receptor–ligand interaction. It is based on Publication
II. Chapter 6 describes the dimerization of JAK2–cytokine receptor com-
plexes in both healthy and pathological states. It is based on Publication
III. Finally, Chapter 7 summarizes the findings and implications of this
Thesis and discusses the potential future directions of the field.
Chapter 2
Biological Background
Living organisms are comprised of biomolecules. This Chapter begins
by briefly introducing the fundamental concepts of three classes of bio-
molecules central to this work: lipids, proteins, and carbohydrates (Fig-
ure 2.1A–C). It then continues by showing how they combine in the envir-
onment of the PM. Nucleic acids, such as DNA (Figure 2.1D), form the
fourth main class of biomolecules but are not the core topic of this Thesis,
so they will not be discussed in detail. Similarly, worth noting are water
and other small inorganic molecules that serve as the medium for all bio-
chemical reactions but are not as such relevant for this Thesis. The Chapter
closes by introducing the molecules of interest in this Thesis: CD44 and its
HA ligand as well as JAKs and their cytokine receptor partners.
2.1 Membranes & Lipids
Our bodies are basically lumps of membranes. If we approximate that a
typical human cell has a diameter of 10 µm, it then has a surface area of
4 × π × (10 × 10−6 m)2 = 12.6 × 10−10 m2 ≈ 10 × 10−10 m2. If we then
consider that human has on average 40 trillion cells [32], the total surface
area of these cells becomes (40 × 1012) × (10 × 10−10 m2) = 40000 m2. To
put this into perspective, this would equal to an area of 200 × 200 m2.
Moreover, this estimate is highly conservative, as it only accounts for the
outer cell membranes even though there are more membrane compartments
inside every cell. As a comparison, the typical surface area of human lungs
is 50 to 75 m2 while that of the skin is 1.5–2 m2. It is therefore obvious that
we are much bigger on the inside than outside — almost every physiological
process is somehow connected to biological surfaces or membranes [1].
The PM is a barrier that separates the interior of a cell from the ex-
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Figure 2.1: Examples of four types of biomolecules. A) Example of a lipid, 1-palmitoyl-
2-oleoylphosphatidylcholine (POPC). B) Example of a carbohydrate, hyaluronic acid. C)
Example of a protein (single domain), CD44. D) Example of a stretch of double-stranded
DNA. Images are generated with the Visual Molecular Dynamics (VMD) software [31].
tracellular space [1]. It is an active boundary that controls the boarders,
maintains vital concentration gradients, transports substances, interacts
with the surroundings, and provides a basis for numerous biochemical re-
actions. Inside a cell, similar membranes define all the cellular organelles,
such as Golgi apparatus, endoplasmic reticulum (ER), mitochondria, as
well as all the other intracellular compartments evolved to perform their
respective functions [1].
The many functions of the PM rise from its complex, mosaic-like struc-
ture [1]. It is a thin, tough, and hydrophobic film of lipids and proteins,
decorated with various levels of attached carbohydrates located mainly on
the extracellular side of the membrane. On the cytosolic side, the PM is
tightly connected to the vast cytoskeleton network. From a physics per-
spective, the PM — like any biological membrane — is a dynamic, two-
dimensional fluid, where most of the constituent molecules move laterally in
the plane of the membrane, whose thickness is roughly 5 nm. The molecules
are held together by noncovalent interactions, rendering the structure flex-
ible and allowing for large-scale movements, such as cell division, without
compromising the integrity of the barrier [1].
The basis for any biological membrane is the lipid bilayer [1,33]. Lipids
are amphiphilic molecules, meaning that they possess both hydrophilic and
hydrophobic moieties. The hydrophilic part can be as simple as a single
hydroxyl group or a more elaborate polar region, such as a carbohydrate
or alcohol moiety. The hydrophobic part typically constitutes fatty acid
chains of varying chemical composition. When exposed to water, they are
unable to participate in the hydrogen bonding network of the surrounding
water molecules. Hence, to maximize the number of hydrogen bonds, the
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surrounding water molecules find their minimum energy configuration by
aligning around the hydrophobic parts of the lipids. Such alignment, how-
ever, increases the order and decreases the entropy of the water molecules
compared to bulk water. Therefore, to reach a more energetically favor-
able state, water tends to interact with the hydrophilic regions of the lipids
instead, such that the hydrophobic regions are forced together and away
from the water molecules. This so-called hydrophobic effect gives rise to
various lipid structures — most notably the bilayer [1, 34].
Lipids are a broad class of molecules. Fatty acids and their numerous
molecular derivatives can all be generally categorized as lipids. These mo-
lecules have various structures, whose common feature is their partial insol-
ubility in water. Moreover, their functions are as diverse as their structures.
In the human body, fats and oils are the main forms of energy storage, phos-
pholipids and sterols serve as structural elements of biological membranes,
while other less-abundant lipid classes share crucial roles as hormones, hy-
drophobic anchors, cofactors, electron carriers, messengers, or emulsify-
ing agents. It is estimated that biological membranes contain hundreds of
thousands of different lipid species’. Yet, only the most abundant of these
membrane lipids, glycerophospholipids, bear relevance for this Thesis. For
a more thorough description of all the lipid types, see Refs. [1, 3, 33].
Glycerophopholipids are the most abundant class of lipids in biological
membranes [33]. Although several lipid species belong to this class, they
all share a common structural architecture. Namely, the backbone of these
molecules is formed by a glycerol moiety. The hydrophobic regions comprise
two fatty acid chains esterified to the first and second carbon of this gly-
cerol backbone. These fatty acids typically have 12–24 carbon atoms which
can be either saturated — i.e., there are no double bonds between the car-
bons — or unsaturated with one or more double bonds. The hydrophilic
region is a polar alcohol head group, joined to the third hydroxyl group
of the glycerol backbone through a phosphodiester bond. The greatest
variance between the various glycerophospholipid species’ originates from
their differences in the polar head group, as there is a plethora of possible
compounds that can be chemically linked to the glycerol backbone [33].
The names of glycerophospholipids are derived from their parent com-
pound, phosphatic acid, according to the type of the fatty acid tails and
the polar head group. For example, name 1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphocholine or POPC signifies that palmitoyl and oleyl fatty acids
are esterified to the first and second hydroxyl group of the glycerol back-
bone, respectively, while a choline alcohol is esterified to the third hydroxyl
position [33].
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2.2 Proteins
Almost all biomolecules in our bodies are either proteins or products of their
action [3]. Proteins constitute the nanoscale machinery that executes the
diverse array of physiological functions our bodies require to stay alive at
every moment. These functions include acting as signaling agents [35, 36],
transporting substances over membranes [37], maintaining the structure
of our tissues [38], generating movement [39], establishing concentration
gradients [40], initiating signaling [41], reading and duplicating DNA [42],
as well as catalyzing the production of other biomolecules [43].
Proteins are formed from 20 amino acid types linked together in a lin-
ear chain via covalent peptide bonds [3]. The sequence of this polypeptide
chain is dictated by the nucleotide sequence of its parent gene. Beyond this
primary sequence, the biological activity of proteins originates from their
higher levels of structural organization. That is, the linear polypeptide
chains fold into different three-dimensional (3D) structures that ultimately
determine their biological function. However, even completely disordered
structures do not always lack function, as many proteins are known to op-
erate in an unfolded state under physiological conditions. Additionally, a
wide array of post-translational modifications (PTMs) [3], such as glyc-
osylations, modify protein structures and thereby also their localization,
role, and degradation [44,45].
2.2.1 Structural Characterization of Proteins
The structure of a protein determines its function. There are four main
levels in the structural organization of proteins: primary, secondary, ter-
tiary, and quaternary [3]. Primary structure describes the sequence of
amino acids in a polypeptide chain and thus sets the basis for the other,
higher levels of organization. Similar amino acid sequences share uni-
form folding patterns, generating homologous proteins or homologs. Of-
ten two homologs are separated by only a few alterations in their amino
acid sequences. Such single amino acid changes can be conservative, non-
conservative, or invariant depending on the chemical similarity between the
exchanging amino acids.
Secondary structure describes the three dimensional folding of local seg-
ments of the polypeptide chain [3]. There are three main categories of sec-
ondary structures in proteins: α helix, β strand, and turn. They each have
well-defined features, such as turn length and translational distance, which
can be used to characterize these structures. Secondary structures are held
together by precise hydrogen bonding networks between subsequent amino
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acids in the chain.
Tertiary structure constitutes the overall topology of the polypeptide [3].
For small (< 150 residues) soluble proteins, this topology predominantly
entails a globular unit, which can also be referred to as the overall fold
of the polypeptide. Large proteins (> 150 residues) may be organized into
multiple structural units called domains. These autonomously folding units
have formed due to a gene duplication or fusion and can often perform their
respective functions without the rest of the protein. The overall fold of a
domain can be expressed based on its predominant secondary structure ele-
ments. For example, domains can be described as α, β, or mixed α/β folds.
Tertiary structure is maintained by both chemical (disulphide bridges) and
physical (hydrogen bonds, van der Waals forces, hydrophobic effect, and
electrostatic interaction) interactions.
Quaternary structure involves more than one polypeptide chain. Here,
the individual chains are termed subunits [3]. Proteins usually form active
complexes with each other, allowing for allosteric regulation and formation
of novel binding sites for their ligands into the areas between the subunits.
These protein complexes are held together by non-covalent, physical inter-
actions between the constituent molecules.
2.2.2 Protein Synthesis, Quality Control & Mutations
The flow of genetic information from DNA to RNA to proteins occurs in
two steps: transcription and translation [3]. Transcription refers to the
synthesis of a single-stranded messenger RNA (mRNA) copy of a segment
of two-stranded DNA. This synthesis is performed by a protein called RNA
polymerase and facilitated by several transcription factors. After additional
processing and splicing, the mRNA strand is transported from the nucleus
to the ER. The second step in the flow of genetic information, translation,
refers to the synthesis of proteins from the mRNA template, occurring in
the ribosomes of the ER. Ribosomes read the mRNA template as units of
three nucleotides or codons at a time. Special start and stop codons define
the reading frame by designating where to start and stop. Translation be-
gins when soluble transfer RNAs (tRNA) bind into the ribosome–mRNA
complex so that the codons from the mRNA and tRNA match. Each tRNA
unit confers one amino acid that the ribosome joins to the growing poly-
peptide chain through a polypeptide bond. The protein is ready after
folding and possible attachment of PTMs in the ER and Golgi complex.
The four-nucleotide code of DNA can produce 43 = 64 different three-
nucleotide combinations. This would allow for 64 different amino acids
if one excludes the designated start and stop codons. However, we only
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have 20 different amino acids, meaning that several codons code for the
same amino acid. This genetic code is well known and applies to all living
organisms [1].
DNA replication is the process by which DNA copies itself during cell
division [3]. Due to the proofreading capabilities of DNA polymerase —
the protein responsible for this duplication — the error rates are as low
as 1 in every 100 million bases [46]. However, when these improbable
but inevitable errors occur in the protein-coding segments or exons of a
gene, they can affect the structure and function of the proteins produced.
Several chemical and physical factors, such as radiation [47], can also induce
mutations. If the effect of a genetic mutation reaches the protein level it
can lead to alterations in the phenotype of the organism. Such alterations
are often neutral or harmful to their carriers, with examples ranging from
color blindness [48] or lactose intolerance [49] to cancer [50] or death.
Small-scale mutations involve an alteration of one or a few nucleotides
within the genome [3]. As a prime example of a small-scale mutation, point
mutations change a single nucleotide in the sequence. Depending on the
change, they might cause a switch of a single amino acid in the final protein
product. If the chemical nature of an amino acid is changed, for example
from basic to acidic, the behavior of the protein might change in a clinically
relevant manner. Point mutations can also introduce a premature stop
codon, resulting in a truncated protein product. Frameshift mutations,
on the other hand, disrupt the DNA sequence by non-multiples of three
nucleotides. They are caused by insertion or deletions of nucleotides to or
from the sequence. Such a complete change in the reading frame typically
leads to a severely altered end product, which can be very detrimental to
the organism carrying the mutation [1].
2.2.3 Membrane Proteins
Biological membranes are crowded with proteins. Indeed, these membrane
proteins constitute roughly 50 % of the volume of the PM [51] and ap-
proximately 30 % of the entire human proteome [52–54]. While the struc-
tural roles of the PM are handled primarily by lipids, proteins carry out
most of its other functions, including the transduction of extracellular sig-
nals through the membrane into the cytosol via receptor proteins, such
as ligand-gated ion-channels [55], enzyme-linked receptors [41, 56], or G
protein-coupled receptors [57]. These proteins bind their respective ligands
on the extracellular side of the PM, resulting in a conformational change
of one protein or dimerization of two or more protein subunits. Such struc-
tural changes then activate the receptors by opening a channel for ions, ini-
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tiating cytosolic enzyme function, or inducing the binding of intracellular
activator proteins. This activation, in turn, initiates chemical signaling cas-
cades within the cell that result in the regulation of gene transcription [1].
Due to the physiological importance of cellular signaling, membrane recept-
ors serve as targets for ca. 50 % of modern pharmaceuticals [4].
Membrane proteins are divided into two main categories — integral
and peripheral membrane proteins — according to their mode of interac-
tion with the membrane [1]. Integral membrane proteins are permanently
anchored to the hydrophobic lipid core. This large group of proteins is fur-
ther divided into transmembrane proteins, whose polypeptide chain spans
the lipid bilayer either one or multiple times, and integral monotopic pro-
teins that attach covalently to only one leaflet of the bilayer through a
lipid anchor. The membrane-spanning segments of transmembrane pro-
teins typically involve a varying number of α helices composed of mainly
hydrophobic amino acid residues. As an example, enzyme-linked receptors,
such as receptor tyrosine kinases (RTKs) [41], possess a single membrane-
spanning helix, while G protein-coupled receptors, such as glucagon re-
ceptor, cross the membrane with seven transmembrane helices [57].
Peripheral membrane proteins are temporarily attached to the mem-
brane lipids or proteins, e.g., through electrostatic interactions and lack
the membrane-spanning component [1]. They therefore readily dissociate
if a polar reagent, such as a concentrated salt solution, is applied to the
membrane.
2.2.4 Enzymes
Enzymes constitute a significant fraction of all proteins. They are a vastly
diverse group of biological catalysts that work by accelerating biochemical
reactions [3]. Many membrane proteins are also simultaneously enzymes,
catalyzing a particular signaling reaction on the cytoplasmic side of the PM
in an activation-dependent manner.
Given the vast heterogeneity of enzymes, their names are usually derived
based on their substrates or the chemical reaction they catalyze, with the
word ending in -ase [3]. They are categorized into six primary classes, such
that oxidoreductases catalyze oxidation/reduction reactions; transferases
transfer functional groups; hydrolases catalyze the hydrolysis of chemical
bonds; lyases cleave bonds by other means than hydrolysis; isomerases
catalyze the isomerization of a molecule; and ligases join molecules together
with covalent bonds [3]. All these classes are further divided into multiple
lower-level categories based on their specific roles. For example, kinases are
transferases that catalyze the chemical transfer of a phosphate group.
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2.3 Carbohydrates
Carbohydrates or polysaccharides act as storage fuels, information carri-
ers, and structural modulators of other molecules [3]. On the surface of
the PM, they form the glycocalyx layer that protrudes outwards from the
membrane (Figure 2.2). This layer provides recognition sites for extracel-
lular molecules and pathogens, thus enabling communication between cells
and their surroundings. The polysaccharide chains in the glycocalyx are











Figure 2.2: Schematic figure of the glycocalyx and plasma membrane. Color coding is as
follows: pale depicts proteins, green describes carbohydrates, and red beads are lipid head-
groups. Blue spheres with numbers highlight key features of the PM environment. Gly-
coprotein dimer (1) spans the membrane and is bound to peripheral membrane proteins
(2) on the cytosolic side. The glycocalyx is formed from long, linear glycosaminoglycans
(3), glycolipids (4), and glycoproteins on the extracellular side of the PM. Channel pro-
teins control the passage of substances through the lipid membrane (6), while signaling
receptors (7) convey the signals from the extracellular space into the nucles.
Glycocalyx Expands the Plasma Membrane
Glycocalyx is a carbohydrate-rich layer lining the PM of almost all cell
types from simple bacteria to complex Eukaryota [58]. It is formed primar-
ily from polysaccharides, which are either soluble or conjugated to other
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biomolecules (Figure 2.2). The size and shape of the glycocalyx vary in
a cell type-dependent manner. Bacterial cells can have only a few cell-
surface oligosaccharide chains, while specific eukaryotic cells can express
macroscopic carbohydrate-rich structures, such as the hair-like appendices
on the blood vessel endothelium [58–61]. The primary functions of glycoca-
lyx include the gating of substances by formation of a functional interface
between cells and their surroundings [58].
Glycosaminoglycans (GAGs) encompass a class of biopolysaccharides
unique to animal cells. They constitute the bulk of the carbohydrate con-
tent in the most prominent eukaryotic glycocali, such as the ones found in
stromal or endothelial cells [58]. Unlike common polysaccharides like starch
or glycogen that are composed of a single repeating monomer, GAGs are
polymers of repeating disaccharide units. This repeating disaccharide unit
consists of uronic acid, such as d-glucuronic acid or l-iduronic acid, and
hexosamine, such as N -acetylglucosamine or N -acetylgalactosamine [58].
Additionally, their varying sulfation patterns often give these structures
an added level of complexity. Due to the carboxylate group in the uronic
acid, GAGs possess a negative net charge and, as a result, assume exten-
ded conformations in solution [62]. GAGs conjugated to proteins and lipids
form proteoglycans and lipopolysaccharides, respectively. These conjugate
structures bind different extracellular ligands and act as structural units,
maintaining the strength and resilience of cells and tissues [58].
N -linked Glycans in Protein Structure and Function
Glycoproteins are another protein-linked class of glycoconjugates. Similar
to proteoglycans, they also house carbohydrates of varying complexity at-
tached to a core protein. However, glycoproteins generally have shorter
(1–20 monomers), more branched, and more diverse carbohydrate residues
attached via specific glycosidic linkages [58]. On a broader perspective,
glycosylation is one of the most common PTMs. It is estimated that over
50 % of all of the mammalian proteins are glycosylated and 1 % of all genes
are coding for enzymes related to glycosylation [3]. The attached glycans
shield the parent protein from proteolytic cleavage, stabilize its specific
conformations, participate in recognition events, and serve as specific name
tags for transport [63].
The linking of oligosaccharides occurs primarily with two mechanisms:
O-linked and N -linked glycosylation [5]. In the O-linked glycosylation,
an oligosaccharide attaches to the hydroxyl group of a serine or threonine
residue via a so-called O-glycosidic link. In the N -linked glycosylation, an
oligosaccharide attaches to the amide nitrogen of an asparagine residue via
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a so-called N -glycosidic link. The N -glycosidic linking requires a consensus
sequence of three amino acids, where the first is the linking asparagine,
the second is anything else but proline, and the third is either serine or
threonine [3]. In such sequence, the hydroxyl group of the serine/threonine
residue forms a hydrogen bond with the carbonyl group of the asparagine
side-chain. This, in turn, increases the nucleophilicity of the amide group in
the asparagine side-chain, thus increasing its affinity for the saccharide. Yet,
the overall propensity of an asparagine residue to be glycosylated depends
also on other factors than its position in the primary sequence, such as the
tertiary structure around the consensus sequence.
Biosynthesis of N -glycans occurs in stages [5]. In the first stage, specific
enzymes assemble a precursor glycan by a stepwise transfer of individual
glycan units to a lipid carrier (dolichol pyrophosphate) on the cytoplas-
mic face of the ER. At a certain point, flippase enzymes recognize the
structure of dolichol pyrophosphate with two attached N-acetylglucosamine
(GlcNAc) sugars and five mannoses (Man) and translocate it to the lumenal
surface of the ER membrane. On the lumenal surface, further mannose
residues are attached to the lipid-linked precursor until the final glycan,
Glc3Man9GlcNAc2, is recognized by an oligosaccharyltransferase that cata-
lyzes its attachment to an asparagine residue of a newly-synthesized poly-
peptide chain. In the second stage, this glycan undergoes trimming and
processing in the ER through conserved glycan remodeling pathways. At
this stage, misfolded glycoproteins are eliminated and correctly folded pro-
teins are further trimmed to produce the final N -linked glycans [5].
After the biosynthesis, all N -glycans share the same Man3GlcNAc2 core
structure, referred to as the core pentasaccharide [5]. The extensions of this
core — i.e., antennae — then define the N -glycans into one of three general
classes: high mannose, complex type, or hybrid [5]. High mannose forms
contain only mannose in their antennae. Complex type N -glycans share
a general Neu5AcXMan1GlcNAc1 structure in all their antennae, where
Neu5Ac refers to N-acetylneuramic acid (sialic acid) and X usually equals
1–3 [64]. Complex type N -glycans also have a fucose residue attached to
the first GlcNAc linked to the asparagine. Hybrid types are a combination
of the other two classes with some antennae housing high mannose and
others having complex type-specific saccharides. Despite this classification,
N -glycans — and glycans in general — typically experience high structural
variance [5,63]. Incorrect carbohydrate structures are generally not correc-
ted by the cell as effectively as, e.g., misfolded proteins [3]. Consequently,
N -glycan profiles of protein extracts typically entail large populations of
different glycan structures [65].
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Hyaluronic Acid
Hyaluronic acid or hyaluronan (HA) is a natural glycocalyx-related GAG
polymer, which — unlike other GAGs — is not conjugated to proteins or
lipids nor sulfonated. Its linear and repeating structure consists of N -
acetyl-d-glucosamine (GlcNAc) and d-glucuronic acid (GlcUA) residues
connected via a β(1→ 4)-glycosidic linkage [12]. These disaccharide units
are, in turn, linked via β(1 → 3) bonds to form polymeric HA. In normal
physiological conditions, HA polymers can consist of ca. 2000–2500 disac-
charide units, spanning lengths of 2-25 µm and molecular weights of up to
6-7 ×106 Da [12,66].
Like other GAGs, HA polymer is polyanionic due to the carboxyl groups
of GlcUA. Yet, HA also has a hydrophobic face due to the axial hydrogens
falling into one face of the disaccharide. This structure gives HA unique
properties, such as an internal swelling pressure, which allows it to act
like a hydrogel — an entangled polymer network that retains water in
its structure. Hence, HA serves as a lubricant and gives tissues, such as
synovial fluid and vitreous humour, their jelly-like consistency [12].
Besides its structural roles, HA mediates a variety of physiological func-
tions, such as embryonic development, immune response, wound healing,
cell motility, and angiogenesis [12]. It also plays a pivotal role in the patho-
genesis of various disease, like diabetes, cancer, pneumonia, kidney dis-
eases, and asthma [12]. This high diversity in HA-related physiological
functions originates from a large number of hyaluronan-binding proteins
(HABPs) [67] that mediate the many functions of HA with different tissue-
specificities, cellular localizations, and regulation mechanisms.
A striking example of the effect of HA on the body is apparent in the
naked mole-rat. This mouse-sized rodent expresses abnormally high mo-
lecular weight HA polymers in its tissues, rendering it immune to cancer
and enabling it to have a life expectancy of over 30 years [68]. As a com-
parison, a mouse of similar size would have a maximum life expectancy of
two to four years. Such findings underline the importance of understanding
the molecular basis of HA recognition by proteins and how it is regulated.
2.4 CD44 Glycoprotein Binds Its Hyaluronan Lig-
and
CD44 is a type I transmembrane protein that, as its primary function,
binds HA [9]. The binding controls cellular adhesion and HA-related sig-
naling through cytosolic accessory proteins [69]. CD44 is encoded by a
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single gene that can produce multiple isoforms, due to the alternative spli-
cing of exons encoding a segment of the juxtamembrane stalk domain. The
canonical form of CD44 consists of 723 amino acid residues that divide into
four domains: hyaluronan binding domain (HABD), stalk domain, trans-
membrane domain, and cytosolic region (Figure 2.3A). From these, only
HABD has been structurally resolved. This 158-residue globular domain is
unaffected by splicing and performs its task of binding the HA ligand even
in the absence of the rest of the protein. It consists of a conserved α/β
fold (Figure 2.3B), called the Link module [10], which is also present in
other carbohydrate-binding proteins, such as TSG-6 [70] and LYVE-1 [71].
In CD44 HABD, the canonical Link module is further extended by N and
C-terminal flanking regions, and stabilized by three disulphide bridges, to-
gether forming the structurally rigid HA binding unit [10].
Binding of CD44 HABD to HA oligomer has been characterized with
X-ray crystallography [11]. This structure illustrates how HA attaches in a
key-to-lock manner to a shallow binding groove on the Link module (Fig-
ure 2.3C–D). One of the most striking features of this crystallographic bind-
ing includes a well-matching surface topology, with a hydrophobic pocket
able to accommodate the methyl group of a bound GlcNAc residue. An-
other noticeable feature is the switch-like behaviour of the nearby R41
residue that can assume two different conformations termed as A and B-
forms. The A–B switch is initiated by torsion in the backbone of the β1–α1
loop (Figure 2.3B) that causes the R41 to flip ca. 90◦ [72]. While the bind-
ing of the HA ligand is the same in both R41 conformations, the B-form
shares a more intimate interaction with the bound ligand [11]. In this inter-
action, the guanidino group of R41 side-chain renders charged interaction
with the hydroxyl group of the bound HA (Figure 2.3D). Hence, the B-
form has been thought to represent a high-affinity conformation stabilized
by the binding of HA [11]. Moreover, in previous mutagenesis studies, R41
has been pinpointed as a critical HA binding residue, as its substitution to
alanine completely terminates the CD44–HA interaction [21,22].
A second, more pronounced conformation shift occurs in the C-terminal
extension of HABD and also influences the ligand binding [23, 24]. This
shift from ordered (O) to partially-disordered (PD) conformation involves
the partial unfolding of the C-terminal flanking region (i.e., strands β8 and
β9) [24]. As a result, the increased conformational freedom enables mul-
tiple positively-charged amino acid residues at the flexible C-terminus to
interact with the bound ligand [73]. Studies indicate that HABD intercon-
verts between the O and PD forms spontaneously in solution, but the PD
conformation is more favorable in the ligand-bound form of the protein [24].







































Figure 2.3: CD44 and its hyaluronic acid-binding domain (HABD). A) Schematic
presentation of the full structure of CD44. B) Naming of the secondary structure elements
on HABD. The structure is extracted from PDB:1UUH [10]. C) HA-binding (dashed
circle) and N-glycosylation (orange beads) sites on CD44 HABD. Residues N120 and
N57 fall on the other side of the domain, as indicated by the arrows. The orientation of
the protein in this surface representation is identical to the cartoon representation in B.
D) Crystallographic HA (yellow beads) binding on HABD [11]. The most important HA
binding residue, R41, is depicted with red in both of its possible conformations.
The binding of HA to CD44 is also heavily regulated by theN -glycosylation
of HABD [14–17, 74, 75]. It contains five N -glycosylation sites (N25, N57,
N100, N110, and N120) [10] from which three (N25, N100, and N110) are
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juxtaposing the crystallographic HA binding groove. Site N25 locates in
the middle of the HA binding face next to two key HA binding arginines
R41 and R78. Sites N100 and N110 lie on the top portion of the HABD,
as presented in Figure 2.3C. Sites N57 and N120, on the other hand, reside
on the opposite side of HABD that lacks any known HA binding residues.
Structurally, the N -glycosylation sites are known to be primarily occupied
by triantennary complex type oligosaccharides, especially in cancerous cell
types [16,65,75]. Such an N -glycan profile means that a significant portion
of the molecular weight and charge of CD44 HABD originates from the
saccharide components.
N -glycans have been shown to define three levels of CD44-dependent
HA-binding [14]. Interestingly, a single cell line can be manipulated with
glycosidases to express all of these three levels. The first level, observed
in untreated cells, is completely inactive to HA binding. The second level
is also inactive but can be induced to bind HA with specific antibodies
or glycosidases. At the third level, the binding is constitutively active.
Glycan-cleaving enzymes, such as tunicamycin and neuraminidases, drive
CD44-positive cells towards the active HA binding level [14,15,75], imply-
ing that N -glycans on CD44 interfere with the binding of HA. However,
some studies have also reported contrasting findings, observing tunicamy-
cin treatment to suppress ligand binding in certain tumor-derived cell lines
and reduce their ability to bind immobilized HA [76, 77]. Based on these
findings, CD44 requires at least some level of glycosylation to bind HA.
Explaining the contrasting findings, the N -glycans of CD44 have been
found to elicit a dual effect on HA binding [17]. First, GlcNAc residues
at the root of the complex N -glycan core have been found to enhance
the binding of HA via an unknown mechanism. Second, sialic acids cap-
pings in the glycan antenna have been observed to inhibit the binding of
HA [14–17, 26, 75, 78]. In fact, the three distinct levels of HA binding are
thought to originate from a varying number of sialic acids, as glycans in
the cells of the inducible HA binding phenotype are known to contain more
α2,3-linked sialic acids than the constitutively active cells [17]. The in-
active cells, on the other hand, are thought to express mainly α2,6-linked
sialic acids, thus rendering them harder to cleave with typical α2,3-specific
neuraminidases [16]. Such regulation by sialic acids can be intuitively ex-
plained by charge repulsion, as both HA and sialic acids share a negative
charge.
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2.5 Cytokine Signaling and Janus Kinases
Cytokines are protein messengers secreted by various cells into the blood-
stream and extracellular space [3, 36]. They act much like hormones, and
the distinction between these two classes of messenger molecules is often
nominal. Typical cytokine-regulated physiological processes include the
immunity response [79] and the production of blood cells and platelets [35].
Cytokines act through receptor proteins [28]. These receptors are a
diverse group of transmembrane proteins that bind cytokines and regulate
growth, survival, and maturation of their parent cells through enzymatic
kinase activation. The efforts to classify this group of proteins is largely
based on their structural features and principles of activation. Among the
various cytokine receptor classes, class I and II receptors lack any intrinsic
signaling capabilities and therefore rely on Janus kinases (JAKs) for the
enzyme function [80] (Figure 2.4A). Structurally, cytokine receptors consist
of an extracellular part containing the ligand binding site, a single-pass
transmembrane (TM) helix, and an intracellular (IC) part that is presumed
to be mostly disordered — i.e., lacking a definite fold [36].
JAKs are a family of cytosolic peripheral membrane proteins. These
non-receptor tyrosine kinases regulate central physiological processes, such
as immunity, development, and growth, via a constitutive association to the
intracellular parts of their cognate cytokine receptors [19]. The JAK family
includes four members, JAK1, JAK2, JAK3, and TYK2, which are struc-
turally homologous, yet activated through different cytokine receptors [56].
The activation occurs generally via the dimerization of two receptor–JAK
complexes. This enables the trans-autophosphorylation of the dimerized
JAKs and leads to the activation of the signaling complex [56]. The
receptor–JAK complexes are typically heterodimers, meaning that both the
receptor and JAK components are different between the two subunits. How-
ever, certain cytokine receptors, such as erythropoietin receptor (EpoR)
and growth hormone receptor (GHR), form only homodimers and bind ex-
clusively to JAK2 [28]. In these cases, it is unclear whether the receptors
dimerize upon ligand binding or exist in a pre-dimerized form that under-
goes some structural rearrangement upon ligand binding. That is, there is
evidence supporting both claims [86,87].
The activation of the receptor–JAK complex leads to the canonical in-
tracellular JAK–STAT signaling pathway [19]. It begins when two adjacent
JAKs trans-autophosphorylate each other via their protein kinase domains
and subsequently transfer the phosphates to the intracellular part of the
cytokine receptor, which leads to the recruitment and phosphorylation of
transcription factors called STATs (signal transducer and activator of tran-






































Figure 2.4: JAK2 and its domains. A) Schematic presentation of a JAK2 monomer
bound to a cytokine receptor. B) FERM-SH2 domain of JAK2. The subdomains of the
FERM-SH2 structure are indicated with markings and gray circles (background). The
intracellular region of erythropoietin receptor is shown in orange. The structure is ex-
tracted from PDB:6E2Q [81]. C) The pseudokinase (PK) domain of JAK2. The structure
is modeled from PDB:4l00 [82] and PDB:5UT3 [83]. D) The tyrosine kinase (TK) do-
main of JAK2. The structure is modeled based on PDB:4OLI [84] and PDB:4IVA [85].
The most important structural elements are highlighted in C and D.
scription). The final step in the cascade is the translocation of the activated
STAT dimers to the nucleus where they regulate their target genes.
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The structure of JAKs comprises ca. 1200 residues divided into four
conserved domains that each have their role in the function of the protein.
At the N-terminal end, the FERM (band 4.1 protein, ezrin, radixin, moesin)
and SH2-like (Src homology-2) domains form a holodomain (Figure 2.4B),
which controls the recognition of distinct cytokine receptors via two known
binding sites for the membrane-proximal Box1 and Box2 sequences of the
receptors [88–90]. The FERM domain is further divided into subdomains
F1, F2, and F3 based on their evolutionary origin. Downstream in the se-
quence, JAKs have two canonical kinase domains, pseudokinase (PK) [91]
and tyrosine kinase (TK) [92], from which the latter is responsible for the
enzymatic activation of the protein (Figure 2.4C–D). The C-terminal TK
domain is activated through a trans-autophosphorylation of two tandem
tyrosines, Y1007 and Y1008, located in the activation loop (Figure 2.4D).
The activated TK domain then phosphorylates specific tyrosines in both
the cytokine receptor and the recruited STAT proteins. The preceding
PK domain is structurally homologous to the TK domain but misses the
kinase activity due to the lack of critical residues required to transfer the
phosphate from ATP to the substrate [93]. Instead, it plays a role in the
regulation of the TK domain by binding to its hinge region and stabiliz-
ing its inactive conformation. However, the full extent of this regulation
mechanism is not known.
The prevailing paradigm states that the autoinhibitory interaction between
the PK and TK domains prevents the trans-phosphorylation of the activ-
ation loop by stabilizing the inactive state of the TK domain [84]. This
view stems from the X-ray structure of TYK2 PK–TK interaction as well
as a similar molecular dynamics simulation-derived structure of JAK2 PK–
TK interaction [84]. In this autoinhibitory interaction, the N lobe of the
PK domain is connected to the N-lobe and the hinge region of the TK
domain. As the activation loop of the TK domain is not directly located
at this interface, this pose most probably acts by hindering the lobe move-
ments of the TK domain crucial for its kinase activity. There are also two
known negative-regulatory phosphorylation sites, S523 and Y570, on the
PK domain. While the exact role of these residues is unclear, Y570 phos-
phorylation is increased upon cytokine activation, suggesting that the TK
domain might phosphorylate it as a possible feedback mechanism [94].
Heterozygous gain-of-function mutations in the genes related to the
JAK–STAT pathway cause a range of physiological disorders [20,95]. From
these, the most common are myeloproliferative neoplasms (MPNs) — a
family of bone marrow disorders, which serve as precursors for blood can-
cers, such as leukaemia [96]. The most common MPNs include essential
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thrombocythemia, polycythemia vera, and primary myelofibrosis. They
are caused predominantly by hyperactivating mutations located in the PK
domains of JAKs [97–100]. These mutations force the JAK-mediated sig-
naling to be constitutively active, which leads to an overproduction of blood
cells/platelets in the cells of the bone marrow. Yet, the exact molecu-
lar mechanisms of these mutations remain elusive. The most commonly
identified mutation is the V617F substitution in the PK domain of JAK2,
which is responsible for over 95 % of polycythemia vera and roughly half
of the cases of essential thrombocythemia and primary myelofibrosis [101].
Furthermore, an array of other oncogenic mutations are known to exist,
especially in the SH2-PK linker segments of JAKs [30].
Unlike other activating mutations, such as R683G or L611S, V617F does
not reside at the PK–TK autoinhibitory interface [84]. It is instead located
proximal to the unstructured SH2-PK linker. Due to this localization, the
mechanism of action for the V617F mutant has remained enigmatic [29].
It has been proposed that the mutation causes a conformational pressure
to the nearby phenylalanine residues, exposing F537 which is normally
covered by F595 of the αC helix [82]. However, the link between this
putative conformational switch and hyperactivation of JAK2 is missing.
V617F has also been proposed to destabilize the SH2–PK linker [102], but
this has also remained as a speculation with little proof. Additionally,
there are certain rescuing mutations, such as F595A, that can suppress
the V617F activity [30]. However, F595A also suppresses other activating
mutations distant from F595, indicating that F595A could act by partially
destabilizing the structure of PK.
A plausible hypothesis states that V617F mediates the ligand-independent
dimerization of the PK domains [29]. Such abnormal dimerization of JAK2
would be driven primarily by the cytoplasmic domains, thereby removing
the need for external cytokine activation. The dimerization of the PK
domains could potentially also disrupt the autoinhibitory PK–TK interac-
tion, thus further facilitating the ligand-independent trans-phosphorylation
of the TK domains.
Chapter 3
Methods
A perfect biophysical technique would be able to track the positions of
atoms in biological macromolecules in vivo. It would also allow the visual-
ization of these particles at any given time or length scale. However, such a
technique does not currently exist. The current research of biomolecules is
instead based on numerous different experimental, computational, and the-
oretical methods that complement each other by covering their respective
ranges of the time and length scales [103,104].
This Chapter provides a brief overview of the modeling and simula-
tion methods employed in this Thesis. It also introduces the simulation
models and analysis tools used to perform this research. For sufficient
background, the Chapter begins by reviewing selected experimental tech-
niques used in biophysical protein research. Namely, these experimental
techniques provide the structural data used in modeling and simulations.
Their ouput also serves as a crucial source of comparison for biomolecular
simulations.
3.1 Selected Experimental Techniques for Study-
ing Proteins
There are several experimental methods to explore proteins. The basis of
these methods lies in genetic engineering techniques designed to express
the protein of interest in sufficient quantities [1]. The following steps typ-
ically involve detection, isolation, and purification of the desired protein
species. After these steps, the protein can be structurally analyzed. This
Section reviews the experimental methods for characterizing the structure
and function of proteins.
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3.1.1 Protein Structure Determination in a Nutshell
Knowing the atomistic structure of a particular protein allows one to study
its atomic-scale properties. It is also a prerequisite for the rational design
of drugs that activate or inhibit the function of the protein. Ever since
the publication of the DNA double helix in 1953 [105] and the first high-
resolution protein structure of myoglobin in 1960 [106], the number of re-
solved protein structures has been growing exponentially [107, 108]. Cur-
rently, RCSB Protein Data Bank (PDB, rcsb.org) is the largest and most
popular online database for 3D structural data of biomolecules, mainly pro-
teins [109]. These experimentally resolved structures are freely available for
researchers. They can be downloaded as PDB files which use a specific text-
based file format for storing the atomic coordinates of the molecules. Each
structure is also assigned a four-character alphanumeric identifier called
PDB ID.
X-ray crystallography
Protein structure determination is dominated by two established meth-
ods: X-ray crystallography and nuclear magnetic resonance (NMR) spec-
troscopy [110]. Today, most of the available protein structures on PDB
are determined with X-ray crystallography. This technique uses beams
of X-rays to resolve the molecular structures inside a crystal [104]. The
wavelength of these X-rays is ca. 1 Å, which equals the length of typical
atomic bond lengths in molecules, making it ideal for scanning the relat-
ive distances between covalently-bound atoms. The basic principle is that
the crystallized structure causes the beam of X-rays to diffract, producing
an interference pattern that can be interpreted to construct a structural
model. X-rays are scattered by electrons, so measuring the angles and in-
tensities of the diffracted beams produces a 3D electron density map of the
target molecule. Properties like mean positions of the atoms can then be
deduced from the electron density map using sophisticated algorithms. The
level of resolution depends on factors such as the quality of the crystals and
intensity of the applied radiation.
Nuclear Magnetic Resonance Spectroscopy
NMR spectroscopy is another experimental technique for solving the 3D
structures of proteins and other biomolecules [104]. It is usually done to
samples in solution, thus removing the necessity for crystallization. NMR
spectroscopy is therefore especially suited for resolving the structures of dis-
ordered proteins, or even some carbohydrates. In this method, the sample
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is placed inside a strong magnetic field, which aligns the magnetic momenta
of the NMR active atomic nuclei with the magnetic field. The sample is
then exited to nuclear magnetic resonance with radio waves that match the
resonant frequency of the nuclei to be measured. After the excitation pulse
is over, the nuclei relax and emit the radiofrequency radiation they had
absorbed in the excitation phase. This emission is detected with sensitive
receivers. The frequencies being absorbed/emitted by the nuclei depend on
their chemical environment, giving each nuclei a unique signal.
Structural determination of biomolecules using NMR is possible because
atomic nuclei are coupled to each other via hyperfine interactions. Mag-
netic dipole–dipole interaction, also known as dipolar coupling, refers to
the direct interaction between two magnetic dipoles. It depends only on
known physical constants and the inverse cube of the distance between the
nuclei, thus allowing one to determine the relative distances between dif-
ferent atoms. Spin–spin coupling, also known as J-coupling, refers to the
indirect interaction between two nuclear spins. It arises from interactions
between the nuclei and local electrons. J-coupling can provide information
on the connectivity of chemical bonds as well as relative bond distances
and dihedral angles. With proper experimental distance and/or dihedral
restraints — and with the basic knowledge of properties, such as peptide
bond geometry and bond lengths — protein structures can then be solved
from the NMR data using the so-called distance geometry algorithms.
In structural studies of proteins, one typically acquires the NMR data
by conducting multiple different types of NMR experiments that each reveal
their own sets of spatial information about the sample in question. These
experiments include two-dimensional homonuclear magnetic resonance-based
methods, such as correlation spectroscopy (COSY), total correlation spec-
troscopy (TOCSY), and nuclear Overhauser effect spectroscopy (NOESY).
Yet another common method is the nitrogen-15 NMR, including the het-
eronuclear single quantum coherence spectroscopy (1H-15N HSQC). It is
currently the most widely used NMR method for resolving the solution
structures of proteins.
Issues with Membrane Proteins
Integral membrane proteins possess large hydrophobic regions, which are
intimately associated with the surrounding lipids. Hence, these proteins
are challenging to study with classical biochemical methods in the absence
of their natural lipid-rich environment. Their purification and crystalliza-
tion, in particular, has proven to be extremely difficult [1]. As a result, the
structural determination of membrane proteins has lagged behind that of
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the soluble proteins [107]. Currently, there is a difference of two orders of
magnitude in the number of resolved structures between soluble and mem-
brane proteins, with over 100 000 available structures of soluble proteins
and only less than 1000 structures of membrane proteins [111, 112]. Al-
though full-length structures are often missing, the structures of the water-
soluble domains of several membrane proteins have been resolved. In many
cases, these partial structures can still help to construct an image of the full
protein or its functions. There are also continuous efforts to design novel
detergents that allow a better purification of membrane proteins [113,114].
Cryogenic Electron Microscopy
Recent improvements in cryogenic electron microscopy (cryo-EM) can offer
help in the structural studies of membrane proteins [115]. In cryo-EM,
samples are cooled fast to cryogenic temperatures and then viewed in their
natural state using an electron microscope [104]. In practice, the cryo-
EM samples are first embedded in vitreous water to preserve and protect
them. They are then plunged into liquid ethane to rapidly freeze the water.
The frozen samples are viewed by directing a high energy electron beam
into them. The image forms as the electrons interact with the matter,
analogous to photons in a light microscope. The rapid freezing prevents
the formation of crystalline ice, which would absorb the electron beam and
thus skew the final image. Overall, generating a structural representation
of the sample molecule requires multiple snapshots from various angles, as
well as additional image processing, to form a 3D view from a series of 2D
images.
One of the advantages of cryo-EM is the lack of crystallized samples [104].
The obtained images thereby reflect the natural state of the studied mo-
lecule under the assumption that the above described procedure successfully
traps the molecule in such a state. Furthermore, with this technique, one
can view entities of various sizes, ranging from macromolecules to entire
cells. Cryo-EM also allows controlling the chemical environment of the
sample, such that it can be viewed in its physiological state. Examples of
cryo-EM resolved structures include the Zika virus envelope and roughly
500 kDa bacterial β-galactosidase protein resolved with 3.8 and 2.0 Å res-
olution, respectively [116, 117]. While the technique has been rapidly de-
veloping over the recent years, it has disadvantages, too. Namely, it has a
poor signal to noise ratio, and it is both expensive and time-consuming to
use.
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3.1.2 Selected Techniques for Studying the Kinetics of Mem-
brane Proteins
Exploring the localization and diffusion of proteins on surfaces like bio-
logical membranes is typically based on fluorescence techniques, where a
single particle or an ensemble of particles are labeled with fluorophores,
excited, and tracked.
Total Internal Reflection Fluorescence Microscopy
When studying the membrane binding of proteins, the background fluor-
escence of the unbound fluorophores often masks that of the bound ones
due to a large difference in their concentrations. Total internal reflection
fluorescence microscopy (TIRFM) is a single particle tracking method with
which a thin region of a larger sample can be visualized, thus allowing a
selective excitation of the surface-bound fluorophores [118]. The method
is based on the total internal reflection of incident light at a glass–water
interface. It is appropriate for studying proteins in live cells with spatial
resolutions of a few nanometers and temporal resolutions of dozens of mil-
liseconds.
Fluorescence Recovery After Photobleaching
Fluorescence recovery after photobleaching (FRAP) is an ensemble-based
fluorescence technique for determining the kinetics of diffusion in live cells
or tissues [119]. It is especially useful in studies of protein binding and
diffusion in a lipid bilayer [120]. The method is based on labeling a sig-
nificant fraction of the studied molecules with fluorophores to produce a
laterally uniform fluorescence intensity and measuring its recovery after a
micrometer-sized fraction of the surface is photobleached.
3.2 The Need of Computer Simulations
Soft matter systems are typically tiny and fragile [7]. They are also com-
plex, meaning they interact in multiple ways and possess various degrees
of freedom, which often results in emergent and hard-to-predict behavior.
Studying these systems using only experimental methods can, therefore, be
challenging. For example, structural biological methods — while providing
the necessary basis for current biophysical research — reveal only a static
image of the molecule under study that lacks all or most of its dynam-
ics [104]. Furthermore, crystallography methods require the crystallization
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of the sample, which typically alters its physiological state. NMR spectro-
scopy, on the other hand, is limited by the size of the sample, as proteins
above 35 kDa start to be challenging to resolve by this method [121]. Other
biophysical methods, like the single-molecule tracking techniques, are good
at monitoring the macroscopic motions of biomolecules, such as their loc-
alization inside a cell or in a lipid bilayer. They are, however, limited by
their poor spatial resolution, so they provide very little atomistic informa-
tion about the studied phenomena.
Computational methods can overcome some of these limitations. In-
deed, the growing computing capacity and improved software optimization
have rendered modeling and computer simulations increasingly appealing
tools to study complex biomolecular systems [103]. Modern simulation
methods allow the user to track the movement of biological macromolecules
in silico with the precision of a single atom. They, therefore, complement
the experiments by probing time and length scales difficult to access using
other techniques. In the big picture, computer simulations can help other
methods when identifying how the biological nanomachines operate and
what makes them to malfunction in a disease. This, in turn, enables us to
design novel treatment strategies against those pathologies.
Computer simulations and models have their limitations, too [122]. The
two most important pitfalls are related to the sampling of the studied phe-
nomena and accuracy of the used models. When can one know that the
simulation is long enough, i.e., the sampling is adequate? How closely does
the used model mimic reality? These are questions that any computational
scientist should bear in mind when designing their research. Hence, these
questions will also be adressed further in the sections below.
Biomolecular simulation engines are constantly being developed and
updated. As with any software, there can be bugs that cause a simula-
tion program to produce incorrect or unexpected results. Furthermore, the
used algorithms and their implementation vary between different software
packages, meaning that their mutual compatibility is not guaranteed. It
is, therefore, critical that computational modeling and simulation tools,
codes, and results are double-checked and compared to earlier data. To
this end, biomolecular simulations are typically done in close unison with
related experiments to constantly verify and improve the used models.
3.3 Modeling of Biomolecules in a Nutshell
Computational research is based on models. They are mathematical de-
scriptions generated to make better sense of the studied systems. In other
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words, a model is a simplification of real-world object or phenomenon that
describes only the most relevant degrees of freedom of the system under
study. For example, in this work, we do not consider the behavior of entire
organisms, cells, or even organelles. Instead, our focus lies on tiny model
systems a few tens of nanometers in size. They describe a patch of the
cellular environment, such as a membrane protein embedded in a simpli-
fied lipid bilayer or two proteins interacting in a slab of water. This is a
viable research approach as long as the questions and hypotheses are ap-
propriately placed. For example, sometimes modeling and simulating even
a single domain of a larger protein is enough if it is essential for the research
question, biologically justified, and verifiable via experiments.
Model as a word can, in principle, mean multiple different things. To
avoid confusion, the nomenclature used in this Thesis is defined as fol-
lows: model system refers to the molecules assembled inside the simulation
cell; model itself entails the interactions, algorithms, and equations used
to capture the behavior of the model system; simulation means the actual
running of this model with a simulation algorithm; modeling refers to the
process of generating a model system or model, which can mean, e.g., the
construction of an appropriate starting structure of a protein.
Homology Modeling Helps to Construct Protein Structures
Experimentally-derived protein structures extracted from, e.g., PDB are
not always intact or otherwise appropriate. Depending on the resolution
they were resolved with, they might lack hydrogens, side-chain-atoms, or
entire regions of the protein. For example, the most flexible loops are
disordered in the crystal, and hence they are often not resolved in the
structure. These typical shortcomings in the available structures mean that
one has to refine the coordinates of the protein to include all the necessary
atoms before a simulation can be initiated. In some cases, the structure of
the desired protein might not be resolved at all. In such cases, one can opt
to use homology modeling to obtain the desired protein structure, provided
that a sufficient, evolutionally-related template structure is available.
Homology modeling refers to the construction of an atomistic model of
a target protein based on a sequence alignment between the target and a
structurally-resolved, homologous template. Homology modeling relies on
the fact that structures are generally more conserved than sequences among
homologous proteins [123–125]. Typically, primary sequences with more
than 40 % sequence identity to the target are regarded as good templates.
For conducting homology modeling, there is a plethora of protein modeling
software from which majority are available as downloadable programs [126]
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or automated webservers [127,128].
In this Thesis, we conduct homology modeling of proteins using a soft-
ware called MODELLER [126, 129]. It is one of the most popular protein
modeling tools available, and it is known to perform well in recent bench-
mark tests [130,131]. One of its main advantages is that it is based on the
Python programming language [132], allowing it to have bindings to various
other modules and dynamic libraries. For homology modeling, MODEL-
LER uses an automated modeling protocol that also allows for manual
intervention, such that one can, e.g., impose experiment-based constraints
to guide the modeling [129]. It also has additional features, such as multiple
alignments of protein sequences, de novo modeling of flexible loop regions,
ability to mutate protein residues, and structure optimization based on an
objective function.
In practice, MODELLER follows the general workflow of homology
modeling [129]. First, it requires three things as input: target sequence,
target–template sequence alignment, and template structure. It then uses a
model generation algorithm called satisfaction of spatial restraints to gen-
erate a three-dimensional structure of the target protein. Based on the
target–template alignments, the algorithm constructs a set of geometrical
criteria and converts them to probability density functions for the location
of each heavy atom in the protein. These restraints then serve as a basis for
several global optimization cycles that use the conjugate gradient energy
minimization algorithm to refine the coordinates of the heavy atoms [129].
Finally, the user needs to carefully assess the viability of the modeled struc-
ture by comparing it to the template. Additionally, when finally simulating
the model structure, it is advisable to run a parallel control system based
on the coordinates of the template structure for comparison.
Imposing Modifications to Protein Structures
Often in protein research, the key questions are related to the chemical al-
terations of proteins, such as mutations or PTMs, and their implications to
function and disease. In case of glycosylations, complete glycan structures
are rarely available beyond the first or second glycan unit attached to the
protein. That is, beyond the first glycan units, the structures are difficult
to resolve experimentally due to their flexible and dynamic nature [7, 27].
Hence, to make structures of glycoproteins more available for researchers,
tools have been developed to in silico glycosylate existing protein struc-
tures. These tools include web-based portals, such as the Glycosciences
web-page [133] and the CHARMM-GUI portal [134], as well as standalone
programs, such as the do glycans tool [135] or the Glycosylator frame-
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work [136].
The paradigm of imposing chemical alterations to protein structures
in silico differs drastically from that used in nature. In vivo, mutations
form at the DNA level, and PTMs are done after translation, often while
the protein is still undergoing folding to its native conformation. In silico,
chemical alterations are always implemented on the native, folded proteins.
It is, therefore, crucial to ascertain that the imposed changes are biologically
reasonable, such that they would not, e.g., affect the folding of the protein.
The best way to obtain this confirmation is to have experimental data for
comparison.
3.4 Molecular Dynamics Simulations
Molecular dynamics (MD) is an established computational simulation method
based on classical mechanics [137]. It presents an appealing method for
studying biomolecular systems because it can provide both structural and
dynamic data at the atomistic level. In the MD method, molecules are de-
scribed as particles attached by springs, whose dynamics are modeled with
Newton’s equations of motion. The result of these computations is the time
evolution of the coordinates and velocities of the constituent particles. It
is called the simulation trajectory. With this simple workflow, the MD
method can model and predict the equilibrium properties of any classical
many-body system.
Despite the straightforward idea behind the MD simulation method,
one has to be aware of its limitations when evaluating its applicability to
a given problem or interpreting results produced by it [137]. For instance,
the classical nature of the MD method means that it neglects the electronic
degrees of freedom. That is, the quantum-mechanical (QM) phenomena,
such as chemical bond breaking or forming, are out of the scope of MD
simulations. This lack of QM phenomena effectively sets a lower limit for
the size of the system reasonable to probe with this method at the level
of individual atoms — i.e., the nanoscale. The maximum timescales are,
in turn, limited by practical considerations, such as the size of the system
(i.e., number of particles), length of the time step, and available computing
capacity.
Simulating biological systems is a constant balancing act between the
available resources and the desired accuracy of the models [122]. Simplify-
ing the system under study — e.g., by focusing on just a small snippet of
it or by changing the simulation model — will increase the available times-
cales, but at the cost of losing potentially important information [137]. As a
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rule of thumb, the duration of a simulation needs to be significantly longer
than the characteristic timescale of the studied phenomenon. These aspects
have to be properly accounted for when designing MD simulation studies.
Practically, MD simulations require four things [138]. First, the simu-
lation begins from a starting structure of the model system. Second, the
user needs to select an appropriate force field to describe the properties
and interactions of the modeled particles. Third, one needs to run the sim-
ulation with a simulation engine, a program that executes the production
algorithm. Lastly, parameter files contain information about the physical
conditions of the simulation. This information includes the choice of times-
cale, time step, frequency of output, temperature control, pressure control,
initial velocities, and other simulation parameters.
3.4.1 Initial Conditions Define the Starting Point for a Sim-
ulation
Before starting an MD simulation, one needs to construct a system con-
taining the studied molecules [138]. In practice, the required information
comprises the coordinates of the constituent atoms and their molecular to-
pologies. The initial coordinates of complex molecules, such as proteins, are
typically based on experimentally-determined structures and acquired from
online databases, such as PDB [109]. The user builds the initial structure
of the entire model system by inserting the constituent particles, including
solvent molecules and ions, into a simulation box. Next, one must construct
the molecular topologies of the particles by defining their basic properties,
such as mass and charge, as well as connections to other particles, such
as bonds and angles. This information then remains fixed during the MD
simulation, meaning that bonds between atoms do not break or form.
Recently, the construction of simple simulation systems has become
more straightforward, due to the increase in computing power [8], availab-
ility of high-resolution structures of biomolecules [109], and the emergence
of more user-friendly tools [139]. For example, model systems can be readily
built using web-based portals that output simulation-ready 3D structures,
topologies, and parameter files [140–145].
After defining the initial structure and parameters, one needs to verify
that there are no excessive forces and that the structure is reasonably close
to its equilibrium state [138]. Otherwise, reaching the equilibrium during
the actual production simulation might take time. The forces in the initial
structure are therefore minimized using an optimization algorithm, such
as the steepest descent or conjugate gradient [138]. After these steps, the
system is generally ready for the production simulation runs, where it starts
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to evolve in time as the forces act on the particles.
3.4.2 Force Field Determines the Molecular Interactions in
Simulations
Force field is a central concept in MD simulations, as it determines the
forces that act on the particles [137]. It entails two parts: the functional
form of the potential energy function and the set of parameters for differ-
ent interaction terms in the function. These parameters typically include
atomic masses, partial charges, van der Waals radii, as well as equilibrium
values and force constants of bond lengths, angles and dihedrals between
two, three, or four bonded atoms. They are typically derived for a given
potential energy function using either quantum-chemical calculations or ex-
periments, such as NMR or vibrational spectroscopy. However, there is no
systematic way to find optimal values for these force field parameters.
In practice, the selection of the force field is usually one of the first tasks
in the MD simulation workflow. In the field of biomolecular simulations,
there are numerous force fields using their own functional forms and re-
lated sets of parameters. Therefore, the choice of an appropriate force field
frequently poses an issue to a computational scientist. While every para-
meter set aims to model the reality as well as possible, there is no unified
model that would be universally good at describing all biomolecules [146].
Furthermore, most of the existing simulation models are not mutually com-
patible. One must, therefore, be aware of the properties of different force
fields and know how each of them is parametrized [122]. Lastly, it is vital
to compare the obtained simulation results to both earlier simulations and
available experimental data [103].
In the MD simulation algorithm, the forces F acting on a particle i are
calculated by taking the negative gradient of the potential energy
Fi = −∇HTotal, (3.1)
where HTotal is the total potential energy function [138]. As noted above,
this potential energy can be divided into different interaction terms that
are grouped into bonded and non-bonded functions, such that HTotal =
HBonded +HNon−bonded.
Bonded Interactions
An MD force field describes covalent bonds with three bonded interaction








Figure 3.1: A schematic illustration of a subsection (atoms A, B, C, D, and E) of
a molecule and its internal degrees of freedom in MD. The bond stretching motion l is
depicted as the relative movement between atoms A and B. Dihedral angle rotation φ is
the angle between planes formed by atoms ABC and BCD, while θ marks the bending of
the angle formed by atoms CDE.
particles, and dihedral twisting between four particles (Figure 3.1). Addi-
tionally, the dihedral term is further divided into two subcategories. First,
the proper dihedral twisting term describes rotation around a bond [138].
Second, the improper dihedral twisting term describes the maintenance of
planarity of four atom groups, such as the chirality of stereospecific centers
or cis–trans isomerism around a double bond. The potentials for these















kξ,ijkl(ξijkl − ξeq)2, (3.5)
where rij is the distance between particles i and j, θijk is the angle between
particles i, j, and k, and φijkl and ξijkl are the angles between planes ijk and
jkl (zero when particles i and l are in the cis conformation). Parameters





φ0ijkl, and ξeq correspond to the equilibrium or reference values for bond,
angle, proper dihedral, and improper dihedral, respectively. Lastly, integer
n describes the periodicity. The force constants and reference values for
bond-stretching and angle bending are normally drawn from experimental
data. The parameters for proper dihedrals are normally obtained from fits
to QM calculations.
The highest-frequency motions (i.e., the bond vibrations) are described
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by the harmonic potential in Equation 3.2. To improve sampling, they can
be kept constant with a constraint algorithm. In practice, one typically
fixes the bond lengths of all covalent bonds involving hydrogen atoms to
a constant value. This treatment removes unnecessary degrees of freedom
and thus allows the use of a longer time step. In this work, we kept the
hydrogen-involving bonds fixed with the LINCS (Linear Constraint Solver)
algorithm [147].
Non-bonded Interactions
Non-bonded interaction terms describe the interaction between two particles
not connected via covalent bonds [138]. These terms include Pauli repul-
sion, van der Waals interaction between any two particles, and electrostatic
interaction between two charged particles. The first two terms are described










where εij is the depth of the potential well between particles i and j, σij is
the distance at which the potential between these particles is zero (i.e., the
size of the particle), and rij is the distance between the particles. Values for
these parameters are obtained through fits to experimental fluid properties,
such as molecular volumes or heats of vaporization [148].
The basis for the repulsive 1/r12 component of the LJ potential lies on
the Pauli exclusion principle, which states that identical fermions cannot
occupy the same quantum state. Hence, particles repel each other at close
distances. The attractive 1/r6 component, on the other hand, stems from
the dispersion forces between two dipoles at longer distances. The decay of
this attrative term with distance has its roots in physics, as freely rotating
induced dipole–induced dipole interaction decays with 1/r6. The exponent
of the repulsive term 1/r12 has, however, been chosen only for simplicity
and computational efficiency, while retaining a sufficient physical accuracy.





where qi and qj are the charges of particles i and j, rij is the distance
between these two particles, ε0 is the permittivity of vacuum, and εr is
the relative permittivity of the medium. In MD simulations, each particle
is usually assigned a partial charge, which is normally derived from QM
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calculations, to realistically describe the distribution of electrons in the
entire molecule.
In practice, it is costly to calculate long-range non-bonded interactions
to every molecule of the system. Hence, the MD algorithm employs cut-
offs, i.e., it omits the non-bonded interactions after a certain threshold
distance [137]. The LJ interaction is typically cut at 1 nm, yet the loss
of potential energy is negligible due to its rapid decay with distance. The
Coulombic interaction, however, remains significant at longer distances,
causing major computational load for the simulation. Therefore, the Cou-
lomb’s law is usually used directly until ca. 1 nm, after which the long-range
electrostatic forces are calculated by interpolating the charge density into a
discrete grid in the reciprocal space and evaluating it using the Fast Fourier
transform. This protocol is called the Particle Mesh Ewald (PME) method,
and it is commonly used in the field of MD simulations due to the enhance-
ment in the runtime it offers [149]. Finally, to keep track of the neighboring
particles within the cut-off radius, MD simulations use neighbor lists [137].
This relatively costly operation is accelerated by updating the lists only at
defined intervals — i.e., not at every simulation time step.
Biomolecules Can Be Modeled with Varying Levels of Detail
In biomolecular research, there are two basic types of classical force fields:
atomistic and coarse-grained [103,137]. In atomistic force fields, each simu-
lated particle describes one atom, whose parameters are derived from exper-
iments, as explained above. These force fields, therefore, reflect reality as
well as possible. They can, for example, accurately describe biologically rel-
evant atomic-scale events, such as conformational dynamics of amino acid
side-chains or hydrogen bonding dynamics. Atomistic force fields can be
further divided into two: all-atom (AA) force fields that provide parameters
for every atom in the system and united-atom (UA) potentials that spread
the contribution of non-polar hydrogens into their host heavy-atoms [150].
UA models accelerate the simulation compared to AA models but loose
some of the atomistic precision, as there is a fewer number of particles to
simulate.
The AA description is often the natural choice for modeling biomolecu-
lar systems if the focus lies on the structural details. Popular AA force
fields used in the MD simulations of biomolecules include AMBER ff99SB-
ILDN [151], CHARMM36 [152,153], GROMOS [154], and OPLS-AA [155].
The research in this Thesis employs the first two of them (AMBER ff99SB-
ILDN, CHARMM36), mainly due to their documented performance and
their extensive selection of parameters for various molecule types, includ-
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ing proteins and glycans [134, 146, 151]. The AMBER ff99SB-ILDN de-
scription is especially suited for proteins but is also compatible with the
GLYCAM06 [156] parameter set for carbohydrates and Lipid14 [157] para-
meters for lipids. Likewise, the AA CHARMM36 protein force field [152]
can be combined with the recently-developed CHARMM36 lipid and car-
bohydrate force fields [158–160].
As noted above, atomistic models form the basis of MD simulation-
based research of biomolecules. However, the sampling of the relevant
length and timescales with atomistic models is sometimes inadequate to
describe large-scale phenomena, such as the binding of a protein complex
to a lipid bilayer or dynamics of the glycocalyx [103]. Coarse-grained (CG)
force fields improve this sampling while still retaining some general level of
the chemical specificity [138]. In practice, CG models simplify the system
by mapping multiple AA heavy atoms into pseudo-atoms or beads. Details
of the mapped particles are then smeared into the parameters of the bead.
This treatment provides ca. a ten-fold reduction in the number of particles
in a given system. The consequent decrease in the number of degrees of
freedom accelerates the simulation significantly [161, 162]. Additionally,
losing the fastest degrees of freedom, such as bond vibrations, allows the
use of longer simulation time step, which further expedites the simulation.
The most common CG force field in biomolecular simulations is the
MARTINI model [161, 162]. Its popularity stems from its extensive se-
lection of molecule types [161, 163, 164] and well-documented tools [139]
that render it effortless to use. Furthermore, it is implemented on three
major MD simulation software: GROMACS [8, 165], GROMOS [166], and
NAMD [167]. MARTINI is predominantly based on four-to-one mapping,
in which one bead represents four heavy-atoms [162]. Currently, the model
has 20 bead types, divided into four main bead types with each having sev-
eral subtypes, to describe the chemistry of typical biomolecules including
proteins, carbohydrates, lipids, and nucleic acids. It also supports both
implicit and explicit solvent models. MARTINI is parametrized based on
thermodynamic properties, mainly partitioning free energies between oil
and water [161]. It thereby combines reasonable structural accuracy with
thermodynamic reproducibility.
Like any modeling, coarse-graining has its pitfalls. When disregarding
microscopic degrees of freedom, one has to make sure that they are not
relevant to the studied research question. For example, atomistic details,
such as hydrogen bonds cannot be reproduced by highly coarse-grained
models. Additionally, the physical basis for any observable may be altered
due to coarse-graining, leading to a wrong interpretation of the underlying
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mechanism. Furthermore, coarse-graining causes entropy loss as molecules
become more simple, which may cause the relation between entropy and
energy to be unphysically balanced [168]. MARTINI is also known to suf-
fer from model-specific issues, such as the overbinding of proteins [169].
One way to overcome these limitations is to combine AA and CG mod-
els in multiscale modeling, where the same system is simulated with both
models in an alternating fashion. Indeed, recent tools have allowed for a
straightforward interconversion between the two descriptions. For example,
the martinize tool converts AA structures of proteins into the MARTINI
CG representation, while the backward tool reverses this by converting CG
models back to AA representation [170].
3.4.3 The Molecular Dynamics Simulation Algorithm
Classical MD simulations model the dynamics of particles by solving New-
ton’s second equation of motion [137]. The algorithm begins by calculating
the forces acting on the constituent particles by taking the negative gradi-
ent of their potential energy function. When it knows the forces acting on
the particles, it will update their positions and velocities from their pre-
vious values through numerical integration. The algorithm then repeats
these steps over multiple discrete time steps to move the atoms. For the
stability of the simulation, the user typically chooses the time step to be
short — i.e., not more than two femtoseconds. In practice, simulations
can span billions of such time steps, producing molecular trajectories that
cover microseconds of the large-scale dynamics of the simulated particles.
For example, small water-soluble protein domains have been simulated for
100–1000 microseconds — enough to observe protein folding [171].
In this work, we used the so-called leapfrog integrator algorithm for the
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such that vi and ri denote the velocity and position of particle i, respect-
ively. Quantity Fi(t) is the force acting on particle i of mass m. Quantities
t and ∆t are the simulation time and time step, respectively.
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In practice, the numerical integration and the rest of the MD algorithm
are executed by a simulation engine. Currently, there is a range of different
simulation engines, and each comes with their own sets of functionalities
that can differ vastly from what the other platforms have to offer [165–167].
In this Thesis, we have used the GROMACS simulation software pack-
age [8, 165]. It is among the most popular MD simulation software avail-
able. For example, it is the main MD simulation engine used by the popular
folding@home project for distributed computing [174]. Its popularity stems
from the fact that it is free and constantly-updated, open-source software,
which can be run on both central processing units (CPUs) and graphics
processing units (GPUs) [175]. It is also one of the fastest simulation soft-
ware packages available with the ability to be readily parallelized using the
Message Passing Interface (MPI) or threads [8]. Furthermore, GROMACS
supports several AA and CG force fields and has a large variety of analysis
and system preparation tools, which can be further expanded by the user
thanks to its open-source nature. The software lacks an in-built molecular
viewer, but one can readily circumvent this issue by using, e.g., the Visual
Molecular Dynamics (VMD) software for visualizing molecular structures
and trajectories [31].
3.4.4 Simulation Conditions
By default, running an MD simulation leads to the microcanonical (NVE)
thermodynamic ensemble [137]. In the NVE ensemble, the number of
particles, the volume of the system, and the total energy of the system
remain constant over time. However, in the related real-life experiments,
temperature is usually constant instead of the total energy of the system.
Such a situation corresponds to either the canonical (NVT) or isothermal–
isobaric (NpT) ensemble. To reach the NpT ensemble in MD simulations,
one must use thermostats and barostats to keep the temperature and pres-
sure of the system fixed. For the NVT ensemble, one needs only thermostat,
as pressure control is not required.
The aim of simulation thermostats is to maintain the temperature at a
fixed level, but at the same time allow it to fluctuate according to the ca-
nonical distribution [137]. A simple way to achieve this is to mimic a weak
coupling of the system to an external heat path. In the so-called Berendsen
thermostat, this is accomplished by scaling the velocity of each particle with
a rate determined by a time constant at each time step [176]. However, this
suppresses the fluctuations of the kinetic energy and therefore fails to pro-
duce the canonical ensemble. As the Berendsen thermostat is nevertheless
efficient in stabilizing the temperature of the system, one typically uses it
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Figure 3.2: On the left: a schematic figure representing the fundamental idea of periodic
boundary conditions in 2D. The unit cell along with the particle trajectories are copied
in all directions and if a particle tries to leave the cell it simply emerges back from the
opposite side. The parameter L is the size of an individual cell. On the right: a real unit
cell is given as a snapshot from real simulation, where the CD44 protein is placed at the
center of the simulation box. Water molecules are omitted from this figure for clarity.
to equilibrate the solvent and ions around the studied macromolecule at the
early stages of the simulation workflow. The subsequent production sim-
ulations employ more sophisticated algorithms, such as the Nosé–Hoover
thermostat [177], able to generate trajectories consistent with the canonical
ensemble.
Typical barostat algorithms are largely analogous to the simulation
thermostats, coupling the system to an external reference pressure. For
example, the Berendsen barostat scales the simulation box vectors and
particle coordinates that lead to first-order kinetic relaxation of the pres-
sure towards the reference pressure [176]. However, the Berendsen baro-
stat is unable to yield the correct isothermal–isobaric ensemble and is thus
used exclusively in the equilibration phase. The production runs typically
employ the Parrinello–Rahman barostat due to its ability to produce the
desired statistical ensemble [178].
Simulation systems are small and finite. Thus, to approximate a vast,
infinite system using a small unit cell, simulations use periodic boundary
conditions (PBCs). They replicate the unit cell or simulation box in every
direction, effectively generating an infinite system formed from copies of
the original cell, as shown in Figure 3.2. During a simulation, only the
coordinates in the original simulation box need to be recorded by the MD
algorithm. Due to PBCs, a particle leaving the unit cell from one side re-
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appears from the opposite side. A particle also interacts with the closest
periodic images of the other particles in the system even if they were in the
adjacent cell. Therefore, the size of the simulation box must be carefully
selected to ensure that molecules do not interact with their own periodic
images, as that would be unphysical. Besides enabling the simulation of
bulk properties with a small unit cell, PBCs introduce translational sym-
metry into the simulation. This property ensures the conservation of total
momentum of the system [179]. Namely, in a finite system, a wall potential
would give rise to finite size effects and abrogate the symmetry as well as
the conservation of momentum.
3.5 Enhanced Sampling and Analysis Methods
Once the simulation trajectory is sufficiently long, it can be analyzed in
multiple ways. In this Thesis, we employ a range of analysis tools, including
both standard GROMACS analysis codes and in-house scripts. The use of
these tools is explained where appropriate. This Section reviews only the
primary analysis techniques used in this work. The errors reported in this
Thesis are standard errors unless stated otherwise.
Computing Free Energies with the Umbrella Sampling Method
The purpose of an MD simulation is to ultimately sample all the states in
which the particles can exist [180, 181]. Given enough sampling, one can
calculate the probability for a particle to be in each state. Such probability
is, in turn, related to the free energy of that state. In practice, however, the
states are separated from others by high free energy barriers. In some cases,
these barriers can be so high that the sampling of the corresponding states
would be highly insufficient with regular equilibrium MD simulations [180].
Free energy methods, such as the umbrella sampling [182], allow the
sampling of states with low probability by overcoming the free energy bar-
riers that separate them. The umbrella sampling technique overcomes these
barriers by imposing additional harmonic biasing potentials, thus forcing
the system to explore also regions of the state space where ergodicity would
otherwise be hindered. The unbiased free energy profile can then be com-
puted by substracting the used biasing potential from the biased, umbrella-
sampled free energy profile [180].
The typical biological model systems involve numerous degrees of free-
dom, ranging from intramolecular motions to intermolecular interactions.
Hence, one typically applies the umbrella biasing potentials to only one or
a few of these degrees of freedom that somehow represent the phenomena
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under study. Such degrees of freedom are called reaction coordinates. The
umbrella sampling technique divides the selected reaction coordinate into
intermediate steps and then applies the biasing potential to each of these
steps [180]. Practically, each step is a separate simulation window set to
sample a particular region of the reaction coordinate.
The sampling is adequate when the system has visited every value along
the reaction coordinate multiple times — i.e., the simulation windows are
long enough to capture the studied phenomenon more than once [180].
Combining the intermediate windows yields a biased probability distribu-
tion along the reaction coordinate, which can be unbiased to give the po-
tential of mean force that approximates the free energy along the chosen
coordinate. This unbiasing is typically conducted with the weighted histo-
gram analysis method (WHAM) [183], which also offers a way to minimize
the statistical error through an iterative process. In GROMACS, WHAM
is implemented under the gmx wham code [184].
Estimating Binding Affinities with the Molecular Mechanics
Poisson–Boltzmann Surface Area Method
When evaluating the binding affinity of two solvated molecules, one would
ideally simulate their spontaneous binding to measure the corresponding
free energy of the process [185]. In such simulation, however, the majority
of the energy contribution would stem from solvent–solvent interactions and
the fluctuations in the total energy would be orders of magnitude higher
than the binding energy. These fluctuations would then lead to slow con-
vergence of the calculation. Although traditional free energy methods, such
as umbrella sampling, would in most cases be ideal for such a calculation,
they often require a considerable amount of resources to accurately capture
these processes. On the other hand, typical drug design-related methods,
such as molecular docking and scoring [186], would estimate the binding
free energy efficiently but not particularly accurately.
The so-called endpoint methods fall between the two extremes. In
these techniques, only the endpoints — i.e., the complex and its unbound
components — are sampled, making them less expensive than umbrella
sampling, but more accurate than simple docking and scoring [187]. Mo-
lecular mechanics Poisson–Boltzmann Surface Area (MM/PBSA) is a popu-
lar endpoint approach for estimating the binding free energy of two solvated
molecules [185, 188]. In MM/PBSA, the free energy of binding ∆Gbind is
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estimated by decomposing it into components according to





where ∆Gbind,vacuum is the free energy of binding in vacuum and the solva-
tion terms ∆Gsolvation describe the solvation free energy of the binding
complex or dimer as well as the individual subunits.
The ∆Gbind,vacuum term can be further divided into
∆Gbind,vacuum = ∆EMM − T∆Snormal mode, (3.11)
where ∆EMM entails the standard MD energy terms from bonded, elec-
trostatic and van der Waals interactions. In practice, one obtains them
by performing equilibrium MD simulations [187, 188]. The last term com-
prises temperature T multiplied by entropy S, which is estimated by a
normal mode analysis of vibrational frequencies. Normal mode analysis
can, however, be computationally expensive and have a large margin of er-
ror. Hence, one can neglect the entropy term if the objective is to compare
two states with a similar entropy, such as a wild-type and a single-amino
acid mutant of the same protein complex.
The free energies of solvation are comprised of two components accord-
ing to
∆Gsolvation = ∆Gpolar + ∆Ghydrophobic. (3.12)
The ∆Gpolar term is obtained by solving the Poisson–Boltzmann (PB) equa-
tion for each of the states (i.e., the complex and both subunits). The hy-
drophobic term is estimated from a linear relation to the solvent accessible
surface area (SASA) [188].
In this Thesis, the MM/PBSA calculations are conducted with the
g mmpbsa tool for GROMACS [189, 190]. It assumes a so-called single tra-
jectory approach, in which the conformational changes that occur upon
binding are considered negligible. With this assumption, uncorrelated snap-
shots of all the molecular states (i.e., the complex and its subunits) can be
obtained from a single MD simulation trajectory of the binding complex.
Analyzing Molecular Distances
The probabilities of two molecular entities to be in contact are calculated
with gmx minist tool, which calculates minimum distances between two
particles or groups of particles. After the minimum distance between the
two entities is recorded, values below a certain threshold (typically 0.6 nm)
are considered as being bound or interacting.
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3.6 Overview of the Model Systems Studied in
This Thesis
This Section describes the simulation systems explored in this Thesis. It
lists the main components of the systems, describes their preparation, and
gives rationale to why such model systems were considered. This Section
also lists the most important physical variables used in each publication,
yet one should refer to the original research papers for the complete sets of
parameters.
Publication I
In Publication I, we provide a detailed view of the binding of HA to its CD44
receptor through unbiased equilibrium MD simulations [191]. To first ac-
quire an idea of a spontaneous receptor–ligand binding, our model systems
consisted of one CD44 HABD and one HA16 oligomer in an uncomplexed
state, as shown in Figure 3.3A. Running a total of nine MD simulations of
such systems then provided us with multiple structures of spontaneously-
formed HABD–HA complexes. Before assembling the systems, we obtained
the coordinates of CD44 HABD from PDB with identifier 1UUH [10]. The
HA coordinates we constructed with the do glycans tool [135]. When
naming the HA oligomers, the suffix indicates the number of saccharide
residues involved in the strand.
Based on the output of the spontaneous binding simulations, we charac-
terized three HABD–HA binding modes, from which one is the previously-
reported [11] crystallographic binding pose (Figure 3.3B). Each binding
mode was then simulated further with three replica simulations. We did
this to acquire further statistics of each pose and to ascertain their stabil-
ity. The complexed HABD–HA structures served also as starting points for
subsequent umbrella sampling simulations, which assessed the affinities of
the binding modes. To set up the umbrella sampling runs, we first pulled
the HA ligand from the surface of the protein to the bulk water. That is,
we selected the Euclidean distance between HA and HABD as the reaction
coordinate for the umbrella sampling free energy calculation. The sub-
sequent analysis required a total of 30 umbrella sampling windows of 100
ns to construct the biased probability distribution along this distance-based
reaction coordinate. Finally, we used WHAM to unbias the distribution and
approximate the free energy of the binding process [184].
To simulate the multivalent binding of CD44 HABDs to a single HA
polymer, we constructed systems of HA64 and two HABDs (Figure 3.3C).
Here, we fixed the HA polymer to an elongated conformation by restrain-










Figure 3.3: Simulation systems in Publication I. A) Starting frame from the spontaneous
binding simulations. B) Example of a CD44–HA binding complex (crystallographic). C)
Starting frame from the simulations exploring multivalent binding. Note that in panels A
and C HA lies in front of the proteins — i.e., it is not bound. HA is depicted as yellow,
CD44 is pale surface, and the key HA binding residues are marked as purple beads.
ing both of its tail-ends with mild (force constant of 10 kJ mol−1 nm−2)
position restraints in the direction parallel to the polymer. As a result, the
HA molecule was able to wobble only along the direction of its long axis.
Namely, its movement in other directions was restricted with stronger re-
straint potentials of 200 kJ mol−1 nm−2 to mimic a rod-like polymer. The
two HABDs were also restrained from their C-terminus to mimic their at-
tachment to the rest of the protein and to the underlying lipid membrane.
Publication II
In Publication II, we in silico glycosylated the CD44 HABD with several
N -glycan profiles (see below) [192]. We aimed to observe how the oli-
gosaccharides behave and fold, especially around the HA binding residues.
The following Sections introduce the selected glycan profiles as well as the
construction of the corresponding simulation systems.
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N-glycosylations on CD44 HABD
Figure 3.4 lists all the N -glycan profiles, or glycoforms of CD44 HABD
studied in Publication II. To model the most realistic N -glycosylations, we
used complex type triantennary N -glycans, having zero or one terminal
sialic acids per antenna (i.e., each non-reducing glycan termini). We chose
this particular triantennary structure because CD44 has been shown to bear
highly-branched, complex type N -glycans on its surface in both wild-type
and ligand-binding subclones of Chinese Hamster Ovary (CHO) cells [75].
Similar glycovariants have also been described in previous reports of the
field [17]. Furthermore, a recent mass-spectrometry study demonstrates
that human CD44 HABD houses triantennary complex type glycans, with
a varying number of sialic acids, as the primary N -glycan structure at the
N25-N110 positions when expressed in mouse myeloma cells [65]. The N120
site, on the other hand, houses mainly triantennary high-mannose type
structures, predominantly without fucosylation [65]. Finally, to model less
cancerous phenotypes, we used shorter oligosaccharides described below.
In the full GlcNAc glycoform, the N -glycans comprise only a single
GlcNAc residue. We chose this glycosylation profile to evaluate the putative
positive effect of the core GlcNAc residues on HA binding [17]. The full
pentasaccharide glycoform also mimics small, neutral oligosaccharides. We
chose this glycan structure as it forms the basis for all the higher-level
glycans, and thus, serves as a good baseline.
Previous studies have shown that mutations N25S and N120S can con-
vert inducible cell lines to constitutively active HA-binders [16]. To emulate
such glycosylation-deficient mutant proteins, we built a partial monosialo
glycoform of HABD, which houses monosialic complex type glycans at pos-
itions N57, N100, and N110 but lacks N -glycans entirely at N25 and N120.
The full asialo glycoform entails complex type glycans terminating to
galactose residues. These glycans mimic the situation after a neuramini-
dase treatment of the inducible cell lines [14]. Namely, the neuraminidase
enzyme cleaves sialic acid residues from the non-reducing termini of the
branched glycans and has been observed to increase the binding affinity of
CD44–HA complexes in several experimental studies [14,15,75].
The full extended asialo glycoform entails oligosaccharides that have
two galactoses in each non-reducing glycan termini. This structure ensures
the glycans are of the same size as the ones in the full monosialo glycoform,
thus enabling the comparison of same-sized glycans (i.e., –Gal–Gal or –Gal–
Neu5Ac). That is, the glycan antennae of the full monosialo N -glycans
terminate to a single sialic acid residue, which is preceded by a galactose
residue. We chose the full monosialo glycoform as it corresponds to the
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N25 N57 N100 N110 N120
N25 N57 N100 N110 N120
N25 N57 N100 N110 N120
N25 N57 N100 N110 N120
N25 N57 N100 N110 N120
N25 N57 N100 N110 N120
N25 N57 N100 N110 N120
N25 N57 N100 N110 N120 N25 N57 N100 N110 N120
Full GlcNAc Full pentasaccharide
Partial monosialo Full asialo
Full extended asialo Full monosialo
Myeloma asialo Myeloma monosialo
Full polysialo
Figure 3.4: CD44 glycoforms used in Publication II. The symbols follow the Symbol
Nomenclature for Graphical Representations of Glycans [193].
48 3 Methods
primary glycoforms found in the inducible cell types [14,17].
In the myeloma asialo and myeloma monosialo glycoforms, glycosyla-
tion sites N25–N110 house fucosylated triantennary complex type glycans [65].
They have either two galactoses or a galactose–sialic acid pair at the end
of each nonreducing terminus. The N120 position houses a non-fucosylated
high-mannose structure, as described in Figure 3.4. The system name re-
flects the number of terminal sialic acids (i.e., zero or one) per antenna on
the N -glycans in glycosylation sites N25–N110.
The full polysialo glycoform entails polysialic complex type N -glycan
structures. In this glycoform, each Neu5Ac residue connects to the next
glycan residue with an α-2,3 bond. We chose these glycans to mimic the
more heavily sialylated glycoforms presumed to be present in the com-
pletely inactive cell-lines. These cells do not bind HA even after a standard
neuraminidase treatment [17].
System construction in Publication II
We deviced two main system setups to explore the behavior of the N -
glycans. In the first setup, we modeled different glycoforms of an isolated
CD44 HABD. Here, we generated three different starting configurations for
the attached N -glycans. Each configuration then served as a starting struc-
ture for five replica simulations of 1000 ns each so that the total number
of replicas was 15 per glycoform. The tested glycoforms included myeloma
monosialo, myeloma asialo, partial monosialo, and full pentasaccharide.
The HA ligand was omitted from these systems.
In the second setup, we constructed spontaneous binding systems where
a HA18 ligand was initially placed at least 2 nm from a glycosylated HABD.
This approach guaranteed a fully spontaneous binding process between the
molecules without any a priori knowledge of factors such as binding modes.
In total, we studied seven glycoforms, each having eight 1000 ns-long sim-
ulation replicas. These glycoforms included full GlcNAc, full pentasacchar-
ide, full asialo, full extended asialo, partial monosialo, full monosialo, and
full polysialo (see Figure 3.4). Finally, we compared the results to the
analogous spontaneous binding simulations of the non-glycosylated HABD
described in Publication I.
Publication III
In Publication III, we modeled an activated dimer of JAK2–TpoR com-
plex [194]. We also simulated individual domains of JAK2 to probe their
dimerization and membrane binding. To this end, we employed both AA
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and CG models. The following Sections explain the construction of the
simulation systems of both descriptions.
All-Atom Systems
We generated an all-atom model of JAK2–TpoR ∆ECD dimer embedded
into a lipid membrane. Here, TpoR ∆ECD refers to a TpoR molecule lack-
ing the extracellular domain, which was found dispensable for the formation
of the active dimer complex in our related experiments (see original public-
ation) [194]. In modeling the dimer complex, we implemented a bottom-up
scheme for the system construction, as indicated in Figure 3.5. Notably,
we used the known dimerization interfaces, JAK2 PK–PK (obtained with
homology modeling from the X-ray structure of JAK1 [82]) and TpoR TM–
TM (obtained from our simulations as well as online structure prediction
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Figure 3.5: Construction of the full JAK2–EpoR dimer model. A) CG model of the
EpoR transmembrane (TM) domain dimer. B) JAK2 pseudokinase (PK) domain dimer.
The two identical domains are separated by colors. C) The full receptor–JAK2 model
embedded in a pure POPC bilayer (pale liquorice). The first JAK2 is depicted in shades
of red and the second in shades of blue. The first EpoR is marked as light green and
the second is marked as yellow. The erythropoietin ligand is colored purple. D) JAK2
FERM domain (blue) bound to the intracellular (IC) domain of EpoR (yellow). E) JAK2
pseudokinase–tyrosine kinase complex. The steps involved in the construction of these
protein models are described in the text as well as in the original paper [194].
At first, we homology modeled the PK–PK interface of JAK2 based on
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the structure of the PK–PK dimer of homologous JAK1 (PDB:4L00) [82]
and a native JAK2 PK domain (PDB:5UT3) [83]. We then linked the
JAK2 PK–PK dimer to two JAK2 FERM-SH2 domains (PDB:4Z32) [90]
that were in complex with the IC segments of TpoR. This FERM-SH2–
TpoR complex was obtained by homology modeling based on the structures
of JAK1–IFNLR1 (PDB:5IXD) [89] and TYK2–IFNAR1 (PDB:4PO6) [88]
FERM-SH2–receptor complexes. When joining the JAK2 FERM-SH2 and
PK–PK dimers, we oriented the FERM-SH2 domain such that its F2 sub-
domain was facing the membrane lipids, since it entails a positively charged
patch of residues presumed to mediate the membrane interaction [90]. Fur-
thermore, we placed the two FERM-SH2 domains apart, as we could not
detect interactions between them. We completed the JAK2 model by mod-
eling the TK domains based on the TYK2 TK domains within the struc-
ture of TYK2 PK–TK (PDB:4OLI) [84] and a native JAK2 TK domain
(PDB:4IVA) [85]. When joining the TK domains to the PK domains, we
opted to use an unstructured linker segment to mimic the extensive inter-
domain flexibility of JAK2 observed in EM imaging [196]. In this manner,
the TK domains have sufficient flexibility in the presumed active state con-
formation to cross-phosphorylate each other. Finally, we linked the dimer
complex to a TpoR TM–TM dimer that we obtained through sampling
from our simulations.
We also constructed an analogous all-atom dimer model of JAK2–EpoR
(Figure 3.5). Since the extracellular domains (EC) of EpoR have been
resolved as a ligand-induced dimer (PDB:1CN4) [197], we incorporated
them into the model to evaluate their possible role in the active dimer
complex. In this full-length JAK2–EpoR model, the FERM-SH2–EpoR
complexes were extracted from a recently-resolved tetrameric JAK2 FERM-
SH2 structure (PDB:6E2Q) [81]. The EpoR TM domains were extracted
from an existing NMR-resolved structure (PDB:2MV6) [198] and dimerized
based on the output of the PREDDIMER web server [195]. The EpoR EC
domains were taken from PDB with identifier 1CN4 [197] and linked directly
to the N-terminal ends of the TM domains. Finally, the JAK2 PK and
TK domains were modeled and attached as described above for the JAK2–
TpoR ∆ECD model. The overall molecular architecture of the JAK2–EpoR
model resembles that of the earlier-built JAK2–TpoR ∆ECD model. Its
main differences are a slightly more tilted orientation and a surprising,
EpoR-mediated dimerization of the JAK2 FERM-SH2 domains that both
stem from the 6E2Q structure. Finally, we embedded both JAK2–EpoR
and TpoR systems into a lipid bilayer using the CHARMM-GUI membrane
builder online tool [140,141] and simulated them for 1000 ns with multiple
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simulation replicas [194].
To study the PK–PK interface more closely, we generated simulation
systems of isolated PK domain dimers as described above. The aim was to
focus on the molecular mechanism of the cancer-inducing V617F mutant [199–
201]. Hence, we modeled the PK systems as both wild-type and V617F.
From the subsequent simulations, we analyzed the differences in the bind-
ing free energies between the two mutant states using the MM/PBSA
scheme [190].


















































Figure 3.6: Workflow in the MM/PBSA calculations of JAK2 PK–PK dimerization af-
finity. At first, all the simulation frames (A) are filtered with an RMSD-based clustering.
The most populated clusters (B) are then subjected to the MM/PBSA calculation, which
yields free energy values for each selected simulation frame (C). These values are then
averaged to obtain an estimate of the free energy of binding (D).
We extracted the data for the MM/PBSA analysis as uncorrelated snap-
shots at 1 ns intervals from the simulations and filtered them with an
RMSD-based clustering using a cutoff of 0.25 nm (Figure 3.6). Two largest
clusters per simulation were then selected for the final MM/PBSA analysis.
This filtering procedure ensured that we were analyzing the relevant dimer
poses in each case instead of the less populated ones, which occurred due
to the flexible nature of the PK–PK interface [82]. In total, we simulated
both wild-type and V617F states with ten 1000 ns replicas.
52 3 Methods
Coarse-grained Systems
To speed up the sampling in the simulations, we generated two system set-
ups using a CG description. First, to determine the structure of the TpoR
TM dimer, we simulated two initially unbound TM helices in POPC bilayer
using the MARTINI model [162, 163]. Here, we considered both wild-type
and the oncogenic W515L mutant. The simulation results showed an X-
shaped dimer to be the most common structure, and as this structure also
agreed with the output of the PREDDIMER tool [195], it was selected
as the starting TM–TM dimer configuration for the JAK2–TpoR ∆ECD
system.
Second, we simulated JAK2 FERM-SH2–TpoR ∆ECD monomers in a
POPC/POPS bilayer (intracellular leaflet contained 10 % of POPS) using
the MARTINI description [162, 163]. We explored this system in three
mutant states: wild type, L224A, and L224E. The goal was to evaluate the
role of the L224 residue in membrane attachment over long timescales (20
µs).
Models & Simulation Parameters
In Publications I–II, we modeled the dynamics of proteins with the AMBER
ff99SB-ILDN force field [151] and carbohydrates with the GLYCAM06 de-
scription [156]. To acquire a more comprehensive view of the binding, we
also replicated selected systems using the CHARMM36 force field [153]. In
Publication III, we used the CHARMM36 force field for the AA systems
and MARTINI 2 for the CG systems [162, 163]. Water molecules were de-
scribed with the TIP3P water model [202] in all the AA systems of this
Thesis. Sodium chloride (NaCl) was also added to neutralize the systems
and to reach the physiological saline concentration (150 mM).
All the proteins considered in this Thesis are human homologs. When
constructing these protein systems, possible missing atoms were filled in
with the MODELLER tool [126]. In these cases, the canonical sequence
templates were taken from the UniProt database [203, 204]. Following the
system construction, every CHARMM36/MARTINI simulation was initi-
ated with the CHARMM-GUI tool [143]. In other cases (AMBER ff99SB-
ILDN/GLYCAM06), the system construction was done manually or using
in-house tools [135]. Publications I–II were run with the GROMACS ver-
sion 4.6.7 [205] and Publication III with the version 2016.
Every simulation was conducted in the NpT ensemble at 310 K tem-
perature and 1 bar pressure. The temperature was coupled separately for
proteins, solvent, N -glycans (Publication II ), HA (Publication I–II ), and
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membrane (Publication III ) using either v-rescale [206] (Publication I–II )
or Nosé–Hoover [177] (Publication III ) thermostat with a time constant of
1 ps. The pressure was coupled isotropically in membrane-exclusive sys-
tems and semi-isotropically in the membrane-inclusive systems using the
Parrinello-Rahman barostat [178]. The simulations were run with the leap-
frog integrator with a time step of 2 fs. PBCs were applied in all three
spatial dimensions. All the covalent bonds involving hydrogen atoms were
constrained with the LINCS algorithm [147]. Trajectories were saved at
every 100 ps. For further details, please refer to the original publications.
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Chapter 4
Binding of CD44 Receptor to Its
Hyaluronan ligand
The structure of a HABD–HA binding complex has been resolved with
X-ray crystallography [11]. This structure defines the binding of HA to
the binding groove on the Link module. However, other studies employing
mutagenesis and NMR spectroscopy have identified HA binding residues
and residue clusters outside this binding groove region [21–24]. Most not-
ably, these studies have mapped prominent HA binding epitopes to arginine
and lysine-rich loci both in the Link module (R29, K38, R41) and in the
C-terminal extension (R150, R154, K158, R162). Majority of the residues
belonging to these potential binding epitopes are structurally distant from
the binding groove and therefore contradict the view of the crystallographic
structure. The PD conformation provides reasoning to why the C-terminal
residues would influence the HA binding, as in this conformational state, the
C-terminal tail is flexible enough to interact with the bound ligand [24,73].
However, this conformational switch does not explain the role of residues,
such as K38, that reside in the Link module outside the binding groove.
HABPs typically contain arginine-rich motifs vital to their ligand bind-
ing ability [67]. In the case of CD44, mapping all the potential HA binding
arginines and other known binding residues onto the surface of HABD re-
veals an interaction surface so wide that it cannot be covered by a single
HA oligomer. Due to such widespread nature of these residues, it has been
suggested that CD44 could have multiple modes of HA binding that would
cover different regions of the HABD surface [10].
Our work in Publication I focused on HABD–HA binding at the molecu-
lar level. The results reveal the existence of three mutually-exclusive bind-
ing modes, including the crystallographic pose analogous to the existing
HA-bound X-ray structure of CD44 HABD [11]. Our subsequent analyses
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focus on characterizing these binding modes, especially in the context of
the previously-identified HA binding residues. Additionally, we show how
the binding modes fit in with the multivalent binding of several HABDs to
a single long HA polymer. Overall, our results create an atomistic picture
of the CD44–HA binding dynamics and thereby expand the knowledge of
this prototypic protein–carbohydrate interplay.
4.1 CD44 Binds Hyaluronan with Three Different
Binding Modes
Our unbiased binding simulations (see Section 3.6) systematically showed
an HA16 oligomer to bind CD44 HABD with three well-defined modes (Fig-
ure 4.1). The first mode of binding is identical to the crystallographic
HABD–HA complex [11], and hence, referred to as the crystallographic
binding mode. In this pose, HA occupies the primary binding groove
while sharing a close interaction with the charged side-chain of R41. Fur-
ther details of this well-documented binding complex can be obtained from
Refs. [11, 72, 207, 208]. The second binding mode describes an interaction
where the ligand lies on top of β1–α1 loop as well as β0, β8, and β9 sheets,
lacking contacts with the hook-like β4–β5 loop, which is closely involved
in the crystallographic binding mode. In this pose, the carbohydrate rings
of HA lie parallel to the surface of HABD, and thus, we refer to it as the
parallel mode. In the third observed binding mode, the HA oligomer occu-
pies a region spanning from the β4–β5 loop to the C-terminus, such that it
assumes a ”vertical” orientation compared to the crystallographic binding.
Hence, we refer to it as the upright binding mode.
In the first set of spontaneous binding simulations, where the HABD–
HA distance was set to 1 nm, three out of four replicas finished in the
parallel binding mode. In the remaining replica, the ligand bound to the
crystallographic binding groove, but detached after ca. 1 µs of simulation
and formed the upright binding complex. In the second set of binding sim-
ulations, where the HABD–HA distance was set to ca. 4 nm, two out of
five replicas finished in the parallel and two out of five in the upright bind-
ing mode. The fifth replica also displayed interaction between HA and the
canonical binding residues, yet in a less defined manner. These observa-
tions show that the observed binding modes are stable at the microsecond
timescales of the simulations. Furthermore, the parallel and upright modes
appear to be more prone to form during the initial stages (i.e., the first mi-
crosecond) of the CD44–HA interaction as compared to the crystallographic
mode.
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Figure 4.1: Key results from Publication I. Snaphots of the A) crystallographic B)
parallel, and C) upright binding modes. HA is color-coded to match the colors in panel
D. D) HA binding probabilities of the experimentally-detected binding residues of CD44
HABD. The black arrows highlight the key arginine residues implicated in HA binding.
The following references were used to gather the list of residues: [10,11,16,21,22,76,209].
Having established the stability of the three binding modes, we set up
simulations of each mode to further analyze them in the context of the
previously-observed HA binding residues. Figure 4.1 lists these experi-
mentally detected residues and shows how they are occupied by HA in our
simulations. Strikingly, the combined fingerprint of all the binding modes
matches that of the experiments, and thus, largely explains the observed
spatial distribution of the residues.
There are two central HA-binding amino acids, R41 and R78, that are
shared by all the binding modes in our simulations. Consistently, they are
also among the most prominent residues whose mutation dramatically de-
creases HA recognition in the related wet-lab experiments [10,11,21,22,209].
Additionally, there are flanking residues more exclusive to a single binding
mode. Mutating these flanking residues in previous experiments has been
known to impair the binding, yet only as compound mutants [21]. This res-
ult could mean that the mutation of these secondary binding residues affects
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the recognition of HA only when they collectively influence the formation
of several binding modes.
Five experimentally-detected residues lack any interaction with HA in
our simulations (Figure 4.1). These residues, however, reside on the ”non-
binding face” of HABD. Conversely, all the other known binding residues on
the ”binding face” of HABD share a significant probability to interact with
the ligand in our simulations, at least in one binding mode. Taken together,
































































































Figure 4.2: Key results from Publication I. Experimentally-observed HA binding residues
(see Figure 4.1) shown as pink beads on the surface of CD44 HABD. The key arginines
are colored purple. The insets show the probability of each key arginine to interact with
HA in each binding mode.
To further characterize the binding modes, we focused on the arginine
residues due to their role as prominent HA binders. Figure 4.2 illustrates
four critical arginine residues and shows what was their contribution to
each binding mode in our simulations. As stated earlier, R41 is the single
most important HA binding residue of CD44 [10,11,21,22,209]. Providing
rationale to its importance, our simulations show that R41 forms a basis
of a central HA binding epitope shared by all the binding modes. That is,
this region renders the highest number of contacts with HA across all the
binding modes (see Publication I for details). Our data also show that each
binding mode is further stabilized by a secondary arginine residue 3–4 nm
away from the central epitope, forming a spatially divided R41-RX motif
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where X depends on the binding mode such that Xcrystallographic = 150,
Xparallel = 154, and Xupright = 162. These findings indicate that CD44
recognizes HA oligomer with more than one binding epitope regardless of
the binding mode.






















Figure 4.3: Free energy profiles of HA8 binding to CD44 HABD with the crystallo-
graphic (blue) and parallel (green) binding modes. The reaction coordinate (ξ) refers to
the distance between HA and residues 75–79 of HABD (i.e., the ”back” wall of the bind-
ing groove). The data are calculated with the umbrella sampling method [182]. The error
estimates (shaded regions in the graphs) are standard errors obtained with the weighted
histogram analysis method [184].
To obtain more quantitative information on the strength of each binding
mode, we measured their binding affinities using the umbrella sampling
technique. Figure 4.3 shows that the crystallographic mode has a binding
free energy of ca. -33 kJ mol−1 (∼ 13.2 kBT, kD = 2.75×10−6 M), while the
parallel mode has a lower value of -22 kJ mol−1 (∼ 8.8 kBT, kD = 1.96×10−4
M). Strikingly, these simulation-derived values are in the same ballpark as
the experimentally-measured ones in the literature (kD = 13–27 µM) [11,
210]. Moreover, the clear difference of ∼ 4.4 kBT in the measured affinities
indicates that the crystallographic mode binds HA more strongly than the
parallel mode. The fact that we observed multiple parallel mode complexes
to form spontaneously in our simulations implies that it forms rather readily
at the tested timescales and could thus represent a metastable state, which
eventually leads to the formation of the crystallographic complex at longer
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timescales. Due to their lower HA binding affinity, the weaker binding
modes might also be used to bind other molecules. Namely, in addition
to HA, CD44 is known to have other ligands, such as osteopontin and
collagen [69].
4.3 CD44 Exhibits Spatially Restricted Motion
Along Hyaluronan
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Figure 4.4: Contour plots describing the contacts of HA residues with two CD44 pro-
teins. The vertical axis lists the HA residues, the horizontal axis depicts the time into the
simulation trajectory, and the contours show the number of HA–CD44 contacts according
to the color bar on the right. The dashed lines guide the eye to see the motion of the two
proteins along the HA strand. Data are shown for two independent replica systems.
As discussed in Chapter 2, the size of HA polymers can vary greatly.
Furthermore, the largest HA fragments have been observed to augment
CD44 binding and clustering, suggesting that multivalent interactions play
a key role in the recognition of HA [210, 211]. Learning more about such
interactions is important because the clustering of CD44 is known to facilit-
ate CD44-mediated signaling via the binding of accessory proteins [69,77].
Hence, we explored the multivalent CD44–HA interactions by generating a
system of two CD44 HABDs and a single HA64 polymer, which we then sim-
ulated with two three-microsecond simulation replicas. Figure 4.4 presents
the main findings from these simulations as numbers of contacts between
HABD and each saccharide residue of HA as a function of time.
In the first run, the other HABD (Figure 4.4, left) moves a stretch of
ca. 20 saccharide residues relative to the HA chain. During this time, the
observed HABD–HA complexes correspond primarily to the parallel and
upright modes, which form spontaneously. These complexes last hundreds
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of nanoseconds, after which they transiently (10–500 ns) dissociate, making
the connection between HABD and HA looser. The relative motion occurs
during these breaks. Although this motion is passive — i.e., does not re-
quire external energy input — it might increase the probability of CD44s
to cluster simply because it limits their degrees of freedom into one dimen-
sion (i.e., parallel to the HA polymer). Moreover, because the motion is
facilitated by the weaker binding modes, it could provide a physiological
justification for the existence of such modes.
In the second run, we observe a spontaneous formation of the crystal-
lographic complex between HABD and HA64 polymer (Figure 4.4, right).
The binding occurs in two phases. First, HABD in the A-conformation
binds to the HA polymer, placing the ligand into the crystallographic bind-
ing groove [11]. Second, after ca. 700 ns, the A-form conformation turns
into the B-form complex, thus completing the binding by enabling more
intimate contact between R41 side-chain and the bound HA. Both phases
can be seen in Figure 4.4 as an increase in the measured contacts. The
initial binding occurs at ca. 750 ns into the trajectory, after which the
molecules stay firmly bound through the rest of the simulation, halting any
relative motion of the protein along the HA64 polymer. These observations
are well in line with another computational study stating that the B-form
is the high-affinity conformation of R41 [72,73]. The observation also agree
with our earlier affinity calculations, suggesting that the canonical crystal-
lographic mode is indeed the primary CD44–HA binding mode.
4.4 Critical Assessment and Future Perspectives
Our results are consistent with previous experimental research. We are the
first to record the steps of spontaneous CD44–HA binding with atomistic
precision, thus confirming the current view of this process. This includes
the A–B conformational transition leading to the formation of the crystal-
lographic complex. Moreover, our residue-by-residue binding profile of the
crystallographic complex — the only previously-known CD44–HA bind-
ing interaction — agrees with both experiments and simulations [11, 72].
Our results also provide novel insight into the recognition of HA, further
explaining the previous experimental findings, such as the role of specific
HA binding residues. What we neglected in our study, however, is the O–
PD conformational transition seen with NMR [23,24]. Another simulation
study has shown that the increased flexibility of the PD conformation can
also explain the role of certain C-terminal amino acids as HA binders [73].
However, while being a potential mechanism for regulating HA binding, the
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PD conformation still does not explain all the observed binding residues.
Furthermore, the idea of multiple binding modes is by no means mutually
exclusive with the O–PD transition. That is, such mechanisms can coexist.
It can be problematic to sample the motion and binding of a relatively
large and flexible ligand (HA8) with umbrella sampling. The usefulness of
the results depends on the choice of the reaction coordinate, as one cannot
sample all the states of the system. We chose the distance between HA
and the binding groove as our reaction coordinate because it is robust to
measure with simulations. As a result, the binding process, starting from
the initial (bound) and final (unbound) states, is well sampled, rendering
the overall estimation of the binding affinity reliable. Further supporting
this claim, our binding affinity values match those of the experimentally-
derived dissociation constants, as noted above.
Our model of CD44 HABD lacked N -glycosylations, which are known to
be important for the recognition of HA [14–17]. However, it is worthwhile
to notice that the most relevant experimental studies have also used non-
glycosylated CD44 constructs to draw their conclusions [10, 11, 209]. For
example, many of the structural studies have used prokaryotic organisms
— that lack the cellular machinery for complex N -glycosylations — to
express their CD44 proteins. Our results from the non-glycosylated systems
are therefore generally comparable with the experimental work. Moreover,
this work without glycans sets the basis for further simulation studies to
explore the role of the N -glycans in the recognition of HA.
4.5 Conclusions
In Publication I, we classified three binding modes of the CD44–HA interac-
tion, termed as crystallographic, parallel and upright. The crystallographic
mode refers to the canonical HABD–HA binding complex. Parallel and
upright modes are two novel binding poses discovered through spontaneous
binding in our unbiased simulations. Combining the residue-by-residue
contact profiles of these three mutually-exclusive binding modes outputs
a binding fingerprint that explains how the experimentally-observed, spa-
tially widespread CD44 residues are all important in the recognition of HA.
That is, the key HA binding residues, such as R41, are shared by all the
binding modes, while the less important residues are exclusive to a single
binding mode. We also recorded a spontaneous binding sequence between
CD44 and HA and demonstrated how the weaker binding modes may be
relevant in the motion of CD44 along a HA polymer. This relative motion
may play a role in, e.g., the clustering dynamics of CD44.
Chapter 5
N -glycans Regulate the
CD44–Hyaluronan Interaction
HA recognition of CD44 is known to be regulated by the N -glycosylation
of HABD [14–17]. Yet, previous studies have reported contrasting findings
regarding the details of this regulation. While some glycan content seems
to favor HA binding [76, 77], at least the presence of negatively-charged
sialic acids generally interferes or inhibits it [14–17, 26, 75, 78]. This in-
hibition is intuitively explained by charge repulsion, as both sialic acids
and HA bear a negative charge. However, given that all the currently
available structural data of CD44–HA complexes are derived from non-
glycosylated constructs [11,23,212,212], the molecular mechanisms under-
lying the glycosylation-dependent regulation of HA binding have remained
elusive.
Based on our previous study, we know that CD44 HABD contains vari-
ous HA binding epitopes [191]. There is also evidence that the prominent
effects of sialic acids as the prime regulators of HA binding could stem from
the competitive inhibition of these HA binding epitopes. For instance, when
neuraminidase was used to cleave the sialic acids from several melanoma
cell lines with different levels of HA binding, the cells with the highest
changes in HA binding levels released the least amount of sialic acids by
weight [213]. This behavior indicates that the presence of sialic acids at
specific sites is more important to HA binding than the overall number
of sialic acids. Likewise, mutating each of the N -glycosylation sites indi-
vidually in the inducible cell lines displayed low levels of binding with the
N100A and N110A mutants but turned into completely active with the
N25A and N120A mutants [16]. This observation implies that N25 and
N120 could be the two most important sites of N -glycosylation regarding
their ability to modulate HA binding. Supporting this notion, previous
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computer simulations have shown sialylated N -glycans at N25 to occupy
critical HA binding residues [27], such as R41, thus indirectly implying that
the ability of these residues to bind HA is decreased in a glycosylated state
of the protein.
In Publication II, we in silico N -glycosylated the CD44 HABD structure
to uncover the role of the N -glycans in the regulation of HA binding [192].
To this end, we simulated N -glycosylated HABD without HA and with
HA in an unbound state (e.g., see Figure 5.1C–F). With these simulations,
we show how complex N -glycans at N25, N100, and N110 cooperatively
cover the canonical binding groove of CD44 HABD. That is, these glycans
form a shield that significantly hinders the accessibility of the primary
ligand binding site. The reduced accessibility of the crystallographic site, in
turn, promotes the formation of the less shielded but lower affinity upright
binding mode. This finding demonstrates a previously-unknown molecular
mechanism to regulate the ligand-binding affinity of receptor proteins by
promoting alternate binding sites through glycosylation.
In this work, we also deciphered how different glycoforms of CD44
HABD recognize HA. The results reveal that N -glycans hinder the bind-
ing of HA by preventing its entry to the binding site via both charge and
steric effects. These observations provide a complete and realistic view into
how different glycan profiles alter carbohydrate–protein interactions on the
molecular level.
5.1 N -glycans Block the Canonical Hyaluronan
Binding Site
To study the folding of the N -glycans on CD44, we constructed systems
of glycosylated HABD lacking the HA ligand. The following simulations
showed the ligand-binding surface of HABD to be consistently covered by
the N -glycans (Table 5.1), especially in the fully glycosylated myeloma gly-
coforms. This covering effect was facilitated by the interlocking of the bulky
glycans next to the crystallographic binding groove, thus effectively form-
ing a glycan shield over the primary HA binding site. An inter-N -glycan
contact map (Figure 5.1A) illustrates that the N -glycans at N25, N100,
and N110 were the main contributors to this glycan shield. Such behavior
was observed with both tested carbohydrate force fields, GLYCAM06 and
CHARMM36, although the latter displayed shorter contacts between the
N -glycans. In addition to the glycan shield, we observed stable electrostatic
interactions and hydrogen bonds between several HA binding amino acids
and N-glycans, especially between the central arginines (i.e., R41 and R78)
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and terminal sialic acids. Such interactions helped to maintain a stable
occlusion of the crystallographic ligand-binding site. Overall, these obser-
vations imply that steric effects play an integral role in the glycosylation-
dependent regulation of CD44–HA affinity.
Measuring the occupancy of HA binding residues by N -glycans revealed
that the residues of the upright mode are ca. 55–65 % less covered by the
glycans than those of the crystallographic and parallel modes (Table 5.1).
This observation held for all the tested CD44 glycoforms. It was also
consistent between the two simulation models, though the absolute val-
ues were ca. 15–25 % lower with the CHARMM36 model compared to
the GLYCAM06 model. This finding implies that the relative propensity
of the upright binding mode might be higher than that of the crystallo-
graphic mode in a glycosylated state of the receptor.
Table 5.1: N-glycan occupancies in the residues of each binding mode. The contributions
of each HABD residue to each binding mode are extracted from Publication I [191].
Data calculated with the AMBER ff99SB-ILDN + GLYCAM06 force field combination
is shown without parentheses. Data calculated with CHARMM36 description is shown in
parentheses. The numbers indicate how much of the HABD surface critical to hyaluronate
binding is, on average, covered by N-glycans.
Binding Myeloma asialo: Myeloma monosialo:
residues occupancy (%) occupancy (%)
Cryst. 50± 13 (38± 8) 51± 8 (33± 7)
Parallel 48± 14 (36± 7) 46± 11 (36± 3)
Upright 29± 12 (24± 4) 30± 7 (20± 1)
Partial monosialo: Full pentasacharide:
occupancy (%) occupancy (%)
Cryst. 35± 18 32± 7
Parallel 34± 17 26± 6
Upright 21± 13 16± 4
Meanwhile, we know that the anti-CD44 antibody MEM-85 inhibits
the binding of HA to a glycosylated HABD [22,214]. To study these inter-
actions further, our collaborators used 15N/1H HSQC NMR to probe the
binding of both HA and MEM-85 to a non-glycosylated HABD. They calcu-
lated the HSQC spectra for free 15N HABD; 15N HABD with 3-fold molar
excess of HA6;
15N HABD with 2-fold molar excess of MEM-85; and 15N
HABD with 3-fold molar excess of HA6 and 2-fold molar excess of MEM-85.
Interestingly, the resulting chemical shift perturbation spectra displayed
coincidental binding of both HA6 and MEM-85. The HA-induced changes
66 5 N -glycans Regulate the CD44–Hyaluronan Interaction

































































































Figure 5.1: Key results from Publication II. A) Number of contact matrix for the five
N-glycans on CD44 HABD ( myeloma monosialo glycoform). The data are averaged over
both time and 15 replica simulations. B) Plot of CD44–HA interface area versus HA–
N-glycans interface area in different glycoforms (see text and Figure 3.4). The data are
calculated by the GROMACS tool gmx sasa. Error bars represent standard errors. C)
and D) show starting structures of glycosylated HABD with (D) and without (C) HA. C)
depicts the myeloma monosialo glycoform and D) corresponds to the full monosialo gly-
coform. E) and F) are corresponding snapshots after 1000 ns of simulation. It should be
noted that these pictures represent only two example cases — more examples are available
in the original publication.
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were localized to the R41-centered epitope as well as residues 75–105, which
correspond to the crystallographic binding groove. The MEM-85-induced
perturbations, on the other hand, were limited to the C-terminal portion of
the receptor. These observations show that HA and MEM-85 have separate
binding sites on a non-glycosylated CD44 HABD — i.e., MEM-85 does not
inhibit HA binding in such case.
In order for MEM-85 to inhibit HA binding to a glycosylated CD44, they
must occupy the same binding site. In the case of MEM-85, we know that
its binding site is centered around the C-terminal residues E160, Y161, and
T163 [25]. As noted above, we have shown by MD simulations that these C-
terminal residues are not perturbed by the attached N -glycans, suggesting
that the binding of MEM-85 is not affected by the glycans. Hence, these
facts point to the C-terminus being a binding epitope for both HA and
MEM-85 in a highly glycosylated CD44 HABD. Supporting this idea, the
C-terminal region forms an essential part of the upright binding mode [191].
Figure 5.2 also shows that the residues in this region are relatively more
prone to bind HA compared to the central epitope residues R41 and R78
when the receptor is heavily glycosylated. Overall, these findings imply that
N -glycosylation regulates CD44 by selectively promoting and inhibiting its
HA binding sites.






















Full asialo Full pentasacc. Full monosialo Partial monosialo
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Figure 5.2: Relative interaction probability of HA with five CD44 HABD arginine
residues in different glycoforms. The data were calculated by counting the simulation
frames in which a contact (see Chapter 3) is present. In this calculation, the first 200
ns of each simulation were excluded as an equilibration period. The obtained values were
normalized with the reference values from the non-glycosylated system ( Publication I) in
order to obtain the relative interaction probabilities. As a result, values above 1 (dashed
line) indicate an increase compared to the binding in the non-glycosylated case, while
values below 1 indicate a decrease compared to the non-glycosylated case.
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5.2 Size and Charge of CD44 N -glycans Control
the Binding of Hyaluronan
We then proceeded to explore the effect of different CD44 N -glycan profiles
on HA binding. To this end, we generated systems in which HA18 and a
glycosylated HABD are initially in an unbound state (see Section 3.6). This
set-up ensured that the binding of the molecules during the simulations was
spontaneous, i.e., independent of the initial placement of the molecules.
Figure 5.1B shows the average final (t = 1000 ns) interface areas of
HABD–HA and HA–N -glycans calculated from the spontaneous binding
simulations. This analysis reveals how the glycan profile affects the binding
of HA. Firstly, the non-sialylated glycoforms — full GlcNAc, full pentasac-
charide, full asialo, and full extended asialo — display an inverse correlation
between the HABD–HA interface area and size of the glycans, indicating
steric effects or ”glycan shielding” to be relevant in regulating the ligand
binding. Secondly, the sialylated glycoforms show reduced binding, clearly
implying that charge repulsion also plays a role in the recognition. The
binding of HA was particularly hindered with the highly sialylated full
polysialo glycoform. The partial monosialo glycoform displayed HABD–
HA interface areas comparable to those of the asialo glycoforms. In the
partial monosialo glycoform, the glycans at sites N100 and N110 were also
less likely to fold over the canonical binding groove as they were unable
to interact with the missing N25 glycan. Strikingly, the equally-sized full
monosialo and full extended asialo glycoforms showed only minor differ-
ences in the measured interface areas, implying that a single sialic acid per
glycan antenna might not be enough to induce extensive repulsion of the
HA ligand.
Taken together, our findings indicate that the CD44 N -glycans control
HA binding via two main mechanisms: steric blocking and charge repul-
sion. The steric blocking means that the largest N -glycans can act as a
switch between high and low-affinity CD44–HA interaction by regulating
the availability of the crystallographic ligand binding site. Accordingly,
the smallest glycoforms may even strengthen the canonical HA binding by
presenting additional interaction sites for the ligand. The charge repulsion
component, on the other hand, refers to the number of sialic acids regulat-
ing the overall strength of the interaction so that a sufficiently high number
of sialic acids can completely block the interaction.
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The modeling of carbohydrates is a challenging task [7, 27, 215, 216]. This
is largely due to the chemistry of these molecules posing unique challenges
to the development of simulation force fields. For example, the typical
properties of carbohydrates — such as, the high number of chiral centers,
stereoisomerism and anomeric effect — result in an enormous state space,
even when dealing with a single monosaccharide. Further complicating the
matters, carbohydrates are often highly branched and attached to other
biomolecules.
Despite these challenges, popular carbohydrate force fields, GLYCAM06
and CHARMM36, have been reported to reproduce some experimental val-
ues, such as intramolecular conformations, reasonably well [156, 217–219].
On the other hand, the GLYCAM06 model has also been shown to produce
abnormal aggregation of β-d-glucose in solution when used with the TIP3P
water model [220, 221]. Furthermore, GLYCAM06 has been reported to
exhibit overtwisting of cellulose fibers in recent simulations [222]. Mean-
while, CHARMM36 is known to underestimate the hydration free energies
of simple monosaccharides when used with the TIP3P water model [220].
These issues show that, like any force field, carbohydrate force fields are
not perfect. They have to be used with caution, carefully assessing the
plausibility of each step. In the publications of this Thesis, we mitigated
the potential problems of the primary force field (GLYCAM06) by repeat-
ing the simulations with another force field (CHARMM36). The observed
trends are similar with both models.
Providing further validation for our approach, our results are consist-
ent with previous experimental findings. For example, our simulations show
that different CD44 glycoforms affect HA binding in the same way — i.e.,
regulated by the charge and size of the N -glycans — as in previous exper-
iments in which the effect of CD44 glycan profiles on its liganding bind-
ing was quantified by affinity capillary electrophoresis [17]. Furthermore,
other studies have also found glycosylations to influence the ligand bind-
ing properties of proteins, e.g., by controlling their conformations [223],
interfaces [224], or orientations [225].
Our findings are also compatible with previous computational work in
which charge-pairing between terminal sialic acids and basic HA binding
residues was determined to cause the inhibition of HA binding. Namely,
we observed similar interactions in our simulations, indicating that charge-
pairing plays a role in maintaining the occlusion of the essential binding
residues.
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We chose the CD44 glycoforms used in this Thesis to be as realistic as
possible, given the current knowledge of these structures [65]. The com-
plex type sialylated glycans mimicked the pathological phenotypes known
to exist in cancer cells [14], while the glycoforms with shorter oligosac-
charides modeled the phenotypes with higher affinity for HA [14,17]. Sup-
porting our choices, our simulations show qualitative agreement with ex-
periments [14, 16, 17]. Still, to fully grasp the role of various glycan pro-
files for HA recognition, we require more information on the link between
different glycoforms and HA binding states on various cell types. Fortu-
nately, there have been recent advances in the development of targeted
glycoproteomic methods for characterizing the glycosylation states of pro-
teins [65, 226–228]. Likewise, the computational methods to study glycans
through modeling and simulation have also developed rapidly over the re-
cent decade [135,136,159,160].
5.4 Conclusions
In Publication II, we in silico N -glycosylated CD44 HABD with several
realistic N -glycan profiles to show how the attached oligosaccharides affect
the binding of the HA ligand. The simulations revealed that the canon-
ical crystallographic binding mode is readily shielded by large N -glycans
due to the steric blocking of the crystallographic HA binding groove. The
weaker upright mode binding site, on the other hand, remained relatively
unaffected by the N -glycans, although the high concentration of sialic acid
residues was enough to abrogate the binding in any case. Together with our
NMR data, these findings suggested that a glycosylated CD44 binds HA
predominantly with the weaker, but less hindered upright binding mode
different from the canonical high-affinity interaction. This implies that the
N -glycans can control which HA binding site is available on CD44, thus
controlling its binding properties in a precise manner and affecting, e.g.,
its clustering dynamics. On a larger scale, our results revealed a novel
regulatory mechanism that uses glycosylations to alter receptor affinity by
inhibiting specific ligand-binding sites while promoting others. These novel
insights into protein–carbohydrate interactions might also be generalizable
to other carbohydrate-binding proteins.
Chapter 6
Molecular Insights into the
Activation of Janus Kinases
The molecular activation mechanism of cytokine receptor–JAK signaling
has remained unclear [29]. The current view states that ligand binding in-
duces conformational changes to pre-dimerized receptor subunits [229,229–
231]. Indeed, pre-dimerization has been observed for both homo and het-
erodimeric class I and II receptors, implying it to be a generic mechanism
for this receptor family [28, 229]. Especially homodimeric class I receptor,
such as EpoR and GHR, have been linked to this activation mechanism
through biochemical and structural studies [28, 231, 232]. Yet, the details
of the proposed conformational changes following ligand binding have re-
mained enigmatic.
In Publication III, we proposed a novel paradigm for JAK activation
through ligand-induced dimerization, which is short-circuited by hyper-
activating oncogenic mutations like JAK2 V617F [194]. The experimental
part of this work introduced a method of dual-colour single-molecule fluor-
escence imaging combined with posttranslational cell-surface labeling. This
technique is able to quantify the monomer–dimer equilibrium of homodi-
meric class I cytokine receptors at the physiological concentration in the
PMs of living cells. The analyses showed TpoR, EpoR and GHR to be
monomeric and randomly distributed in an inactive state but effectively
dimerize upon introducing their respective ligands. In addition, quanti-
fication of the monomer–dimer equilibrium between the ligand and JAK2
V617F-induced dimerization revealed that the mutation amplifies the di-
merization and activation in an additive manner. These findings suggested
that dimerization is the primary activation mechanism for receptor–JAK2
complexes and involves an intracellular JAK2 PK domain-mediated dimer-
ization interface. However, the molecular details of this activation mech-
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anism remained unclear.
The modeling and simulation part of the work (Author’s contribution)
entailed constructing and simulating a realistic 3D model of an activated
cytokine receptor–JAK2 dimer embedded in a lipid bilayer [194]. The
goal was to evaluate its stability and dynamics as both the wild-type and
V617F mutant to reveal the atomic-level details unreachable by experi-
mental means. We also used smaller models of the putative dimerization
interfaces to measure the differences in affinity between the wild-type and
mutant dimers. Here, our results of JAK activation agree with experimental
data, strengthening the validity of the observations. We also revealed a
novel membrane binding interaction of JAK2 that forms a prerequisite for
the productive dimerization and activation of the receptor–JAK complexes.
6.1 JAK2 Signaling is Preceded by Dimerization
To reveal the mechanistic details of the dynamics of cytokine receptor–
JAK2 dimers, we modeled two full-length JAK2s bound to either TpoR or
EpoR in a pure POPC lipid bilayer. Both TpoR–JAK2 and EpoR–JAK2
systems showed the receptor complex to assume a stable upright orient-
ation, with the long axis of the JAK2 FERM-SH2 domain aligning with
the membrane normal, while the TK domains were residing the furthest
from the lipids, as shown in Figure 6.1A. This orientation was maintained
by a strong interaction between the FERM domain and the inner leaflet
of the lipid bilayer. Integral to this interaction is the hydrophobic residue
L224 as well as the positively charged patch of residues around the α3
helix in the F2 subdomain (Figure 6.1C). Notably, the interaction did not
change when we altered the membrane composition from the pure POPC
bilayer to a slightly more realistic POPC/cholesterol/phosphatidylinositol
4,5-bisphosphate (PIP2) (68/30/2 mol %) bilayer (Figure 6.1E). In fact,
this change should only strengthen the membrane affinity of FERM as the
positively charged patch in the F2 subdomain can interact with the negat-
ively charged PIP2 lipids.
The coupling between the FERM domains and the lipids enforces an
orientation of the receptor complex that, in turn, enables optimal inter-
subunit interaction involving the putative PK domain-mediated dimeriza-
tion interface [82]. Indeed, the dimerized PK domains maintained a stable
interaction through the simulations, as shown in Figure 6.1D. The FERM-
SH2 domains also displayed a relatively high number of inter-subunit con-
tacts, but mainly due to their large surface area and proximity — i.e.,
these domains did not form dimers in our simulations. The TK domains,






































































Figure 6.1: Key results from Publication III. A) full-length JAK2–EpoR dimer model
embedded in a pure POPC bilayer. The snapshot is taken at 1000 ns into a simulation
trajectory. B) Membrane binding of the F2 subdomain of FERM. The side-chains of
L224 (green) and the seven Lys and Arg residues (orange) in α3 change their orientation
upon binding a membrane. C) Probability of residues in the F2 subdomain to interact
(distance < 0.6 nm) with the lipid head groups (top) and the acyl chains (bottom). D)
Domain–domain contacts between the JAK2 dimers. The PK domains (i.e., the intracel-
lular dimerization interface) show stable interaction. E) Angle of the FERM domain —
and thus the whole protein complex — when bound to TpoR in a POPC bilayer, mixed
POPC/cholesterol/PIP2 bilayer, and when bound to EpoR in a pure POPC bilayer.
initially modeled in a flexible conformation relative to the other domains,
were found to be the most mobile parts of the signaling complex, sharing
only transient inter-subunit contacts. This behavior supported the notion
that dimerization — either through ligand binding or mutation — is driven
by the inter-subunit PK–PK interface, which shifts the equilibrium away
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from the intra-molecular PK–TK autoinhibitory interaction, thus freeing
the TK domains to undergo trans-autophosphorylation [101]. This model
is further supported by the fact that certain autoactivating mutations, such
as R683S, are also located in the PK–TK autoinhibitory interface [30,233].
The recently-resolved X-ray structure of JAK2 FERM-SH2 domain in
complex with the cytoplasmic tail of EpoR showed dimerization of the
FERM domains through the juxtamembrane region of the bound EpoR [81].
The most prominent interactions in this EpoR-mediated dimer involved π
stacking between the side-chains of EpoR W283 and JAK2 W298. Nat-
urally, we also included them into our EpoR–JAK2 model that was con-
structed based on the X-ray structure [81]. However, these interactions
dissociated during the simulations, and as a result, the juxtamembrane
W283 residues were found to associate with the lipid bilayer (Figure 6.2).
This behavior implies that the EpoR W283-mediated dimerization is rel-












































Figure 6.2: Top panels: snapshots at the beginning (left) and end (right) of a JAK2-
EpoR simulation. Yellow and red beads highlight EpoR W283 and JAK2 W298, respect-
ively. The arrows on the right highlight the dissociation of EpoR W283 from the crystal-
lographic dimerization pocket [81]. From JAK2, only the FERM domains are shown for
clarity. Bottom panel: histogram of EpoR W283 and JAK2 W298 minimum distances.
Color-coding indicates the simulation time. The initial state (at t = 0) corresponds to
the highest probability peak seen at a distance of ca. 0.4 nm.
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The most distinctive feature of the full JAK2–receptor model was the sur-
prisingly stable interaction between the F2 subdomain of JAK2 FERM and
the lipid bilayer. Residue L224 has a crucial role in this interaction, act-
ing as an anchor that protrudes into the hydrophobic core of the bilayer.
Highlighting its role in the membrane interaction, L224 is conserved in
all JAK family members. Structurally, it is fully solvent-accessible in all
known JAK structures and located in the C-terminal end of the α3-helix
of FERM, which is surrounded by a patch of positively-charged residues
presumed to mediate the membrane interaction, especially with charged
lipids [234]. Upon membrane-binding, the L224-containing end of the α3-
helix protrudes into the membrane core, leaving the charged residues on
the level of lipid head groups, as shown in Figure 6.1B.




















Figure 6.3: A) The importance of L224 for the membrane binding of JAK2. The left
panel shows a CG model of a wild-type JAK2 FERM-SH2 (blue) attached to TpoR (TM
and IC domains, orange). The right panel shows the same construct having the L224E
mutation. Arrows indicate the orientation of the FERM domain and its variation during
the simulations. B) Angle of the FERM domain relative to the membrane normal in the
tested JAK2 mutants. The measured vector was defined with the Cα atoms of residues
221 and 490. C) The AA starting structure of a wild-type JAK2 PK–PK dimer used in
our simulations. D) Example of a final (t = 1000 ns) JAK2 PK–PK structure obtained
from our simulations. The V617 residues (yellow beads) are highlighted with circles.
To better evaluate the role of L224 in the membrane binding at micro-
second timescales, we generated CG models of two JAK2 mutants, L224A
and L224E, bound to a TpoR ∆ECD monomer in a POPC/POPS bilayer
and compared them to an analogous wild-type system. The resulting simu-
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lations showed a striking difference in the orientation of the wild-type and
L224E constructs: the wild-type remained in the stable, upright membrane
binding pose, while the L224E assumed a less defined and more tilted ori-
entation, as shown in Figure 6.3A–B. This difference shows that the single-
residue membrane anchor is a crucial factor in orienting and stabilizing the
entire protein complex.
When replicated in experiments, JAK2 L224E dramatically reduced the
ligand-independent dimerization and activation of TpoR, EpoR, and GHR
coupled to JAK2 V617F, suggesting that a proper membrane binding is
required for JAK2-mediated dimerization [194]. Furthermore, FRAP ex-
periments showed that the binding stability between JAK2 FERM-SH2 and
TpoR at the PM of living cells was approximately 20-fold lower in case of
the L224E mutant, implying that the orientation of the FERM-SH2 domain
is essential for a productive receptor–JAK interaction. Further supporting
this notion, visualization with TIRFM illustrated that JAK2 FERM-SH2
wild-type (fused to a green fluorescent protein) interacted more strongly
with a surface micropatterned with either TpoR, EpoR, or GHR than the
corresponding L224E mutant. All in all, these results confirmed that JAK2
L224E does not destabilize the conformation of JAK2, but affects the ori-
entation of the protein complex, as predicted by the MD simulations.
6.3 Oncogenic Mutations Overstabilize the Dimer
To evaluate the differences between JAK2 wild-type and V617F, we simu-
lated both of these forms as isolated PK–PK dimers (extracted from JAK1
PK–PK dimer; PDB:4l00; Figure 6.3C) and calculated their respective
binding free energies using the MM/PBSA scheme [190]. These calcula-
tions yielded consistently lower free energy values for the V617F dimer
relative to the wild-type with ∆∆GV617F = −32.7 ± 16.2 kJ/mol. This
computationally-derived value agrees qualitatively with the experimentally
measured binding free energy difference of ∆∆GV617F,exp = −5.2 ± 1.1
kJ/mol, calculated from the measured dimerization levels of receptor–JAK
complexes [194]. The apparent quantitative discrepancy between the two
values likely stems from the systematic underestimation of entropy by the
MM/PBSA approach. Hence, these results imply that the V617F mutation
indeed works by overstabilizing the cytosolic PK–PK dimerization interface.
Structurally, the JAK1-derived PK–PK interface involves the flexible
SH2–PK linker segments, the αC helices, and the loops containing the
V617 residues but in a conformation that lacks a direct V617–V617 in-
teraction [82]. However, the unstructured nature of the SH2–PK linker
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segments increased the conformational heterogeneity of the interface dur-
ing the simulations, producing structures where a more direct inter-subunit
V617–V617 contact was present (e.g., see Figure 6.3D). This finding high-
lights the power of MD simulations in creating motion into static X-ray
structures and reveals a potential model for the JAK2 PK–PK interaction
close to that of the X-ray structure of JAK1.
6.4 Critical Assessment and Future Perspectives
The structures of the receptor–JAK dimers presented in this Thesis are
models. That is, they might not represent native structures with 100 %
accuracy. However, the models were built and verified based on various
internal consistency checks. First, the coordinates of the individual do-
mains were extracted from experimentally-resolved structures and then
combined into a full structural model (see Section 3.6 and the original
publication [194]). Second, the important interfaces, such as the PK–
PK and FERM-SH2–receptor interactions, were taken from X-ray struc-
tures [81, 82]. Third, the inter-domain dynamics observed with MD sim-
ulations are similar to that observed previously with EM imaging of the
homologous JAK1–gp130 holocomplex [196]. Fourth, the obtained simula-
tion results agree with our experiments. So while the structure of our dimer
complex is a model, it is well justified and passes all the internal consist-
ency checks. In the future, techniques like cryo-EM are poised to eventually
reveal the full structure of a homodimeric cytokine receptor–JAK complex,
thus updating the view of its structural details. Meanwhile, our models
represent the state-of-the-art understanding of this molecular interaction.
The CG simulations form a relevant part of the work in Publication III.
As explained earlier, it is imperative to know the limitations of CG models
to utilize them correctly. In this work, the CG simulations provided extra
guidance when predicting the possible TpoR TM–TM dimer poses. Des-
pite the well-documented issues with the used MARTINI 2 force field [169],
these simulations were not done in isolation — i.e., the obtained results
were consistent with the outputs of other structure prediction tools (see
Chapter 3) and can therefore be considered reliable. We also used a CG
model when evaluating the role of JAK2 L224E mutant by changing the
representative bead type from hydrophobic to charged. Therefore, the con-
clusions drawn from these systems are purely physical in nature, lacking
any biological alterations, such as conformational changes, that would be
out of the scope for CG models. This renders the observations solid and
justifies the use of the CG model to speed up the sampling.
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Despite the insight provided by Publication III, there are still questions
regarding JAK activation that remain to be answered. For example, lipids
are known to module the function of several membrane receptor proteins.
However, very little is currently known about the link between membrane
properties and JAK activation. In addition to lipids, the activation most
probably involves considerable domain reorganization, such as the dissoci-
ation of autoinhibitory PK–TK complexes in cis as well as the association
of the PK–PK domains in trans. Yet, the exact sequence of events leading
to the activation remains to be elucidated. In the future, one could perform
this task with either cryo-EM or long timescale MD simulations.
Although Publication III provides an explanation for JAK2 V617F and
other related mutations at the PK–PK interface, there are a plethora of
other activating mutants associated with JAKs or their cognate cytokine
receptors [30]. Several mutations have, for example, been identified near the
ATP-binding pocket of the kinase domains [30]. Another mutation hotspot
resides in the TM domains of the cytokine receptors [235]. For instance,
TpoR has been shown to harbor multiple clinically identified mutants in
this region [235–237]. The exact mechanism of all these mutations and
their relation to the activation mechanism remain elusive, although it is
possible — and supported by the results of Publication III — that at least
the majority of the TpoR TM mutations overstabilize the dimerization of
the receptor complexes similar to JAK2 V617F.
6.5 Conclusions
Publication III provides novel insight into the activation of homodimeric
cytokine receptors via JAK2. We modeled and simulated JAK2 both as
individual domains and as full-length dimers together with its homodimeric
cytokine receptor partners EpoR and TpoR. The simulations were integ-
rally bridged to corresponding wet-lab experiments. Our data together
with the data from the experiments clearly illustrated that the dimeriza-
tion of two receptor–JAK2 subunits controls the activation of their kinase
function. This dimerization can occur either via ligand binding or through
autoactivating mutations, thus explaining the mechanism of operation of
several clinically relevant JAK2 mutants, such as V617F. Finally, the joint
view of our simulations and experiments suggests that a proper membrane
anchoring of JAKs is a prerequisite for their receptor binding and dimer-
ization. Overall, these findings increase our knowledge about the onset
of blood cancers. They could also open up novel avenues for drug design
against diseases, such as MPNs.
Chapter 7
Discussion
Today, computers are an invaluable tool in biophysical research. Simula-
tion methods have evolved to not only complement experiments but also
make predictions. Thanks to the ever-increasing computational power as
well as the continuous development of novel algorithms, we can now see
in silico how protein complexes behave at biologically relevant timescales.
Moreover, this trend will continue in the future, which means that modeling
and simulations will become increasingly important tools in understanding
the emergence of diseases.
In this Thesis, modeling and MD simulations were used to study how
structural modifications affect the regulation and activation mechanisms of
two cell membrane-related proteins: CD44 and JAK2. Both proteins have
a key role in human physiology, especially in cellular signaling. Due to their
central role, both proteins are implicated in cancer — among other diseases
— either through malfunctions, such as mutations, or abnormal expression
profiles of proteins and glycans.
This Chapter places the work done in this Thesis into a broader context,
speculating the type of added value it offers to the respective fields of both
proteins. The Chapter also explores how each field is moving forward and
highlights some of their key findings from the recent years. To this end, it
places a special focus on outstanding medical issues and druggability.
7.1 Summary of Key Findings
In Publications I–II, we discovered that the interaction of the multifunc-
tional cell-surface glycoprotein CD44 with its HA ligand might be more
complex than previously thought. That is, in our simulations of non-
glycosylated CD44, we found that the receptor binds HA with three dif-
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ferent binding modes. The strongest of these modes is the canonical crys-
tallographic interaction mode. The two novel binding modes — termed as
parallel and upright modes — are likely to represent metastable states of
the receptor–ligand interaction, yet they may nevertheless be physiologic-
ally relevant in processes, such as the clustering of CD44. Strikingly, our
subsequent simulations showed that the upright binding mode could be-
come a more dominant CD44–HA interaction mode in a glycosylated state
of the receptor, as the crystallographic binding site is heavily covered by
the N -glycans. This observation could mean that N -glycans can control
receptor activity by promoting some binding sites over others, and raises
a question of whether this is a common mechanism for many glycosylated
receptor proteins.
In Publication III, we built a realistic model of an activated cytokine
receptor–JAK2 dimer. Based on this model and experimental data, we
then showed how clinically recognized mutations — most importantly the
oncogenic JAK2 V617F — overstabilize the intracellular dimerization in-
terface formed by the JAK2 pseudokinase domains. We also showed that
the dimerization and activation rely on a proper membrane-anchoring of
the receptor-JAK dimer. These results shed light into the emergence of my-
eloproliferative neoplasms — a diverse form of blood cancer whose onset is
tightly associated with JAK2 mutations.
Taken together, modeling and simulations offer an appealing route to
study nanoscale systems composed of biomolecules. For example, the soft
and dynamic glycans would be relatively tedious to probe as precisely with
other techniques. Similarly, piecing together realistic models of large pro-
tein complexes through modeling and simulations offers information that
is currently not available in other ways. Therefore, the methodology in
this Thesis is appropriate and serves significant benefits to the respective
research projects. In the future, structural biology efforts will most likely
yield more accurate information on both CD44 and JAK2, thereby corrob-
orating or debunking the models proposed here. Given the fast development
of novel software and force fields, it is also likely that future simulations will
be able to generate complementary knowledge on these systems. However,
for now, our models and results endow new prospects for understanding
the medical issues related to both CD44 and JAK2.
7.2 CD44 in Future Cancer Therapeutics
Due to its central role in human physiology and pathology, the CD44–HA
interaction has been studied extensively for the past three decades [69,238,
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239]. After a period of rigorous basic research, the focus of the studies is
shifting towards a more applied science, aiming to exploit the CD44–HA
interaction in the treatment of human disease, most notably cancer [240].
As both CD44 and HA are overexpressed in various tumor types, they
provide an attractive target for selectivity between healthy and diseased
tissues [69,239,241–243].
Currently, there are three main strategies of exploiting the CD44–HA
interaction in the treatment of cancer [240]. In the first strategy, HA is used
together with nanocarriers to deliver specific anti-cancer drugs directly to
the tumor tissue expressing high numbers of CD44 [240, 244]. Such solu-
tions typically involve the conjugation of HA to liposomes [245], polymeric
nanoparticles [246], or development of HA-based, self-assembling nanocar-
riers [247, 248]. In the second strategy, HA is directly conjugated to an
anti-cancer drug [249]. These type of solutions are actively pursued as
they improve the bioavailability of drugs and reduce their toxicity. The
third strategy involves targeting CD44 directly with humanized antibod-
ies [250–253]. Indeed, several antibodies have been shown to block CD44
on cancer cells [240]. This blocking causes the cells to have a weaker inter-
action with the tumor matrix and, as a result, induces apoptosis [254].
A few promising CD44–HA-based treatments have reached the early
stages of clinical trials. For example, ONCOFIDTM-P is a Paclitaxel–HA
conjugate for the treatment of bladder cancer [249]. The conjugate enters
tumor cells via CD44 internalization and localizes into lysosomes. The
release of the drug in the lysosomes then results in a signaling cascade that
leads to the apoptosis of cancerous cells. After phase I clinical trials showed
a positive treatment outcome in 9 out of 15 patients, phase II studies were
initiated with a larger cohort [255]. In addition to the ONCOFIDTM-P
platform, antibodies have been designed to target CD44. U36 and BIWA
(bivatuzumab) are two promising antibodies targeting the CD44v6 splice
variant of CD44 [250–253]. Both drugs have reached phase I in clinical
trials where they displayed significant antitumor potential in the treatment
of head and neck squamous cell carcinoma. However, when bivatuzumab
was conjugated to cytotoxic agent mertansine in another phase I study,
severe skin toxicity was reported [256].
All these recent findings highlight the potential of CD44 in future cancer
therapeutics. Yet, despite these developments, there are still blind spots
in CD44 biology. Most notably, the full structure of the receptor is miss-
ing. Similarly, there is no high-resolution structure of CD44 with a realistic
glycan profile — something where modeling and simulations can, however,
offer indispensable benefits, as we have shown. This Thesis, as well as
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earlier research, have already demonstrated how important N -glycans are
for the ligand-binding function of CD44. Hence, their role in future thera-
peutics should not be neglected. Perhaps targeting both CD44 as well as
specific tumor-related glycan profiles would in future offer benefits for the
targeted delivery of anti-cancer drugs and antibodies. Moreover, models
used in this Thesis could be expanded to include more components of the
glycocalyx, thus generating an in silico platform to study drug permeability
through the PM in a realistic and controlled manner.
7.3 Towards Disease-specific Janus Kinase Inhib-
itors
Recently, there have been multiple attempts to shed light into the struc-
tures of full-length JAK–receptor complexes [194,257,258], from which our
study is a prime example [194]. The common goal is to acquire insight
into the operational principles of these molecules through better structural
understanding. Similar to our research, MD simulations have played an
integral role in the recent modeling-based efforts [257,258].
Parallel to our research, another study constructed a model of an active
JAK2–EpoR dimer using experimental mutagenesis and X-ray data as a
guide [257]. Their active dimer complex resembles that of ours in the
overall arrangement of the domains, but they used different dimer interfaces
for the PK–PK and TM–TM dimers that they discovered through MD
simulations. In their structure, the clinically-relevant hotspot residues,
including V617, interact with F3 subdomain of FERM in cis, thus forcing
a suitable orientation for productive PK–PK interactions in trans. Similar
to our research, these interactions would be overstabilized in the V617F
mutant case. However, this view is different from our, more direct V617F–
V617F contact model, and highlights the need for further studies.
Recently, a three-domain structure of human growth hormone receptor
(HGR) was modeled based on data combined from small-angle X-ray scat-
tering, NMR spectroscopy, X-ray crystallography, and MD simulations [258].
This model does not include JAKs but illustrates the dynamic nature of
a single cytokine receptor subunit. Together with our study, these efforts
highlight the growing trend of using modeling and MD simulations com-
bined with other biophysical methods to uncover full-length structures of
cytokine receptors and JAKs.
The final goal in this research is to design better treatments against
disorders in JAK–STAT signaling [259, 260]. JAKs have posed a tempting
target for drug developers ever since the discovery of the role of V617F in
7.3 Towards Disease-specific Janus Kinase Inhibitors 83
oncogenesis [97–100]. Currently, some JAK inhibitors are already on the
market, while many others are being developed [261]. Current inhibitors
work by targeting the ATP-binding site of the TK domains, thus inhibiting
their phosphate transfer properties. As a conserved and well-defined pocket,
the ATP-binding site is relatively easy to target with drugs. There is also
some evidence that ATP binding might stabilize the active conformation of
the PK domain, which could in turn help to maintain the V617F-induced
aberrant activation [93]. However, current JAK inhibitors do not provide
effective selection between V617F and wild-type proteins [261].
The first JAK inhibitor to be approved by the Food and Drug Admin-
istration (FDA), as well as the European authorities, for the treatment of
MPNs is ruxolitinib [262–264]. It is an orally effective drug that inhibits
both JAK1 and JAK2 [264]. It has produced positive results and is thus ap-
proved for the treatment of myelofibrosis and polycythemia vera. Another
JAK inhibitor, fedratinib, was also recently (2019) approved by the FDA
for the treatment of these conditions [265]. Unlike ruxolitinib that binds
the ATP-binding pocket, it is not known how fedratinib binds JAKs, yet it
has shown selectivity towards JAK2 over the other JAK family members.
Along with these drugs, there is a plethora of other compounds currently
in clinical trials that show promises of treating MPNs effectively [266–269].
There are also several JAK inhibitors — either on the market or being
tested — for the treatment of other diseases, such as rheumatoid arth-
ritis [270, 271], inflammatory bowel disease [272], psoriasis [273], or atopic
dermatitis [274].
A remarkable breakthrough in the field would be to develop a drug
selective to the V617F mutant [20, 83]. Based on our research, this could
be achieved by targeting the dimerization interface of the JAK2 PK domain
instead of the ATP-binding pocket of the TK domain. This is because the
PK–PK interface is central to the mutation-driven overactivation of JAK2.
Such a strategy could optimistically lead to a decrease in JAK2 dimerization
and thus a diminished overactivation of the JAK–STAT pathway. However,
the dimerization interface of the PK domain might be challenging to target,
as it lacks specific binding pockets like the ATP binding site. Another
option arising from the results of our study could be to target the TM
domains of cytokine receptors with fat-soluble drugs that partition into lipid
membranes. Hindering the dimerization of the TM domains might shift
the equilibrium towards inactive receptor–JAK monomers, thus reducing
overactivation. Membrane-partitioning drugs could also be designed to
interfere with the membrane binding of the FERM domain — again a
feature that we have shown to affect the activation of JAK signaling.
84 7 Discussion
It remains to be seen whether these strategies prove to be useful in
treating diseases that are caused by malfunctioning JAKs. Nevertheless,
our study has provided novel insight into the activation of JAKs, and thus,
expanded these potential new avenues for treating JAK-driven disorders.
7.4 Concluding Remarks
This Thesis expanded the knowledge on two cell-surface proteins, CD44
and JAK2. Our models provided an atomic-scale understanding of these
proteins and their ligands that can be expanded upon in future research.
On a broader scale, we also showed how biomolecular modeling and sim-
ulations can help probe nanoscale phenomena that are difficult to access
through other techniques. Similarly, this work highlighted how model-
ing and simulations can bring added value to biomolecular research when
bridged to experiments. Such a combined setting allows a particular prob-
lem to be examined from several time and length scales, thus unlocking fea-
tures that would remain hidden if investigated from only one perspective.
Given that most future research problems require similar multidisciplinary
problem solving, it is vital that researchers of all disciplines are aware of
the available techniques — both computational and experimental — and
can communicate with each other effectively.
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Kräutler, V., Oostenbrink, C., Peter, C., Trzesniak, D., and
van Gunsteren, W.F., The GROMOS software for biomolecu-
lar simulation: GROMOS05. Journal of Computational Chemistry,
26(16): 1719–1751. 2005.
[167] Phillips, J.C., Braun, R., Wang, W., Gumbart, J., Tajkhor-
shid, E., Villa, E., Chipot, C., Skeel, R.D., Kale, L., and
Schulten, K., Scalable molecular dynamics with NAMD. Journal of
Computational Chemistry, 26(16): 1781–1802. 2005.
[168] Riniker, S., Allison, J.R., and van Gunsteren, W.F., On de-
veloping coarse-grained models for biomolecular simulation: a review.
Physical Chemistry Chemical Physics, 14(36): 12423–12430. 2012.
[169] Javanainen, M., Martinez-Seara, H., and Vattulainen, I., Ex-
cessive aggregation of membrane proteins in the Martini model. PLoS
One, 12(11): e0187936. 2017.
[170] Wassenaar, T.A., Pluhackova, K., Böckmann, R.A., Mar-
rink, S.J., and Tieleman, D.P., Going backward: a flexible
geometric approach to reverse transformation from coarse grained
to atomistic models. Journal of Chemical Theory and Computation,
10(2): 676–690. 2014.
104 References
[171] Shaw, D.E., Maragakis, P., Lindorff-Larsen, K., Piana, S.,
Dror, R.O., Eastwood, M.P., Bank, J.A., Jumper, J.M., Sal-
mon, J.K., Shan, Y., and Wriggers, W., Atomic-level charac-
terization of the structural dynamics of proteins. Science, 330(6002):
341–346. 2010.
[172] Hockney, R.W., Goel, S., and Eastwood, J., Quiet high-
resolution computer models of a plasma. Journal of Computational
Physics, 14(2): 148–158. 1974.
[173] Van Gunsteren, W.F. and Berendsen, H.J., A leap-frog al-
gorithm for stochastic dynamics. Molecular Simulation, 1(3): 173–
185. 1988.
[174] Beberg, A.L., Ensign, D.L., Jayachandran, G., Khaliq, S.,
and Pande, V.S., Folding@ home: Lessons from eight years of
volunteer distributed computing. In 2009 IEEE International Sym-
posium on Parallel & Distributed Processing, pp. 1–8, IEEE. 2009.
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